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Introduction 1
2. Introduction 
 
The ADAM (a disintegrin and metalloprotease) family is a transmembrane proteins 
belongs to the Zinc protease superfamily. ADAM proteins are related to snake venom 
metalloproteases (SVMPs) proteins that are secreted in the venom of certain 
rattlesnakes. The three major classes of SVMPs encode either pro-and metalloprotease 
(P-I), pro-, metalloprotease and disintegrin (P-II), or pro-, metalloprotease, disintegrin 
and cysteine-rich (P-III) domains. ADAM proteins are most closely related to the P-III 
SVMPs, such as jararhagin and atrolysin A, but unlike their SVMP counterparts, most  
ADAM proteins are membrane anchored (1, 2, 3).   
 
Members of the superfamily have a modular design, characterised by the presence of 
metalloprotease and integrin binding function, and a cytoplasmic domain that in many 
family members harbour binding sites for various signal transducing proteins. The 
ADAMs family has been implicated in the control of membrane fusion, neurogenesis, 
and cell migration, as well as processes like muscle development, fertilization, cell fate 
determination, modulation of NOTCH receptors and processing of the pro-
inflammatory cytokine i.e. TNFα (4). The ADAM family plays important roles in 
"ectodomain shedding", the process by which biologically active, soluble forms of 
cytokines, growth factors, and their receptors are released from membrane bound 
precursors. Collectively these ADAMs are capable of four potential functions: 
proteolysis, adhesion, fusion, and intracellular signalling. 
ADAMs 1, 8-10, 12, 13, 15-17, 19-21, 24-26, 28, 30, 31, 33 and ADAMTSs 1-9 
contain the Zinc binding site in the metalloprotease domain. These ADAMs (or their 
processed forms) most likely function as Zinc proteases. Natural substrates are 
presently known for only a handful of the ADAMs. They include: TNF for 
ADAM17/TACE, NOTCH for ADAM10/KUZ (5,6). 
 
2.1 Classes of Metalloproteases 
 
Zinc proteases are subdivided according to the primary structure of their catalytic sites 
and include gluzincin, metzincin, inuzincin, carboxypeptidase, and DD 
carboxypeptidase subgroups (7). Metzincin form a large and relatively diverse family 
that shares common sequence motifs and folding patterns. Based on their structure 
and function, the metzincins to which the ADAMs belong can be further divided into 
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four subfamilies: serralysins (large bacterial proteinases), astacins, matrixins (matrix 
metalloproteases, MMPs), and adamalysins (reprolysins or SVMP) (8,9). The 
adamalysins subfamily also contains the class III snake venom metalloproteases and 
the ADAM-TS (thrombospondin) family (10). Matrixins are responsible for the 
extracellular matrix degradation and remodelling, and play important roles in 
development, wound healing, and in the pathology of diseases such as arthritis and 
cancer (11). Adamalysins are similar to the matrixins with regard to their 
metalloprotease domains, but contain a unique integrin receptor-binding disintegrin 
domain (10,11). The domains organisation of different metalloproteases is shown in 
figure.1. 
 
Figure. 1. General domain structure of the ADAMs, SVMPs, ADMA-Ts and MMPs 
(10). 
  
2.2 ADAMs domain organization  
 
Like SVMPs, ADAMs consist of a signal sequence, a propeptide, a metalloprotease, a 
disintegrin domains, and a cysteine-rich region (11). Many ADAMs exhibit several 
additional C-terminal domains compared to the structure of the SVMPs. They share an 
epidermal growth factors repeat (EGF) domain and a transmembrane domain followed 
by a cytoplasmic tail suggests that these proteins may serve as signal transducers 
between the extracellular and intracellular space via cell-cell or cell-matrix interaction. 
(13,14,3). The ADAMs share a pre-domain for secretion and pro-domain that is 
processed after activation, followed by a metalloproteinase/catalytic domain. In some 
ADAMs this catalytic domain contains Zinc ion.  
The common structural elements of these proteinases are four parallel and one anti-
parallel β-strands as well as three long α-helices arranged in a typical sequential order 
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(8,9). Members of the superfamily of zincins encode a metalloprotease domain that is 
similar to the SVMP Zinc-dependent proteases. This domain may contain the consensus 
sequence HEXGHXXGXXHD and ADAMs containing these sequences are 
catalytically active (8,15,16). Structural analysis suggests that the three histidines (H) 
and a water molecule tetrahedrally coordinate the Zinc and a specific Glu residue acts 
as the catalytic base (17). Whereas second glycine (G) allows a turn. The presence of an 
Asp residue after the third His is one of the major features that distinguish reprolysins 
from other metzincins that contain a Met-turn structure (18). In the presence of a 
conserved methionine residue beneath the active site that is called the “Met-turn”, the 
motif can be classified as metzincins. It is believed that the “Met-turn” structure folds 
back and stabilizes the Zinc ligands (9,18,19).  
Unlike other Zinc protease families, however, ADAM proteins have two distinguishing 
characteristics, first, the intact Zinc-binding site is absent in several ADAMs, including 
2-7, 11, 14, 18, 22, 23 and 29 (12). Therefore, these ADAMs are not considered Zinc 
proteases. Second, the metalloprotease domain is not retained in several mature 
ADAMs. For example, both α and β subunits of fertilin (ADAMs 1 and 2 respectively) 
lack the protease domain in their mature forms (1). 
Some ADAMs lack C-terminal domains (ADAM11 and soluble ADAM12), they may 
be active as soluble proteins (25,24).  
The crystallography has shown that members of this superfamily share an active site 
made up of two domains: an “upper” N-domain and a lower “lower” C-domain. The 
two halves are separated by the active-site cleft with the catalytically active Zinc ion at 
its bottom (9). The crystal structure of the catalytic domain of human ADAM17 
(TACE, TNF-α-converting enzyme) has been determined and it contains the same 
structural elements as the other members of the metzincin superfamily (19).  
 
2.3 Expression and distribution of ADAMs 
 
ADAMs are widely distributed in many organs, tissues, and cells, such as brain, testis, 
epididymis, ovary, breast, placenta, liver, heart, lung, bone, and muscle. 
ADAMs were first identified in Guinea pig sperm (20), but have since been found in 
vertebrates, as well as in Caenorhabditis elegans, Drosophila (6), and Xenopus (21,23). 
They are not present in Escherichia coli, Saccharomyces cerevisiae, or plants. 
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Expression profiles of the ADAMs can vary considerably. In mammals, many of them 
(including ADAMs 2, 7, 18, 20, 21, 29, and 30) are predominantly expressed in the 
testis and/or associated structures. Other members (ADAMs 8, 9, 10, 11, 12, 15, 17, 19, 
22, 23, 28, and 33) show a more broad somatic distribution (table.1).  
Several ADAMs also have an alternative spliced form that diverges before the TM 
domain, leading to the production of a soluble, secreted form. These ADAMs include 
11 (22), 12 (24), 17, 22 (25), 28 (26), 29 and 30 (27) (table.1). It is not known whether 
all the membrane-anchored ADAMs have a soluble counterpart generated through 
either alternative splicing or shedding from the cell surface. Having both soluble and 
membrane-anchored forms allows ADAMs to regulate events not only on or near the 
cell surface, but also at distance from cells.  
 
Table 1. Human ADAMs function, expression and some with defined alternative 
splicing   
 
ADAM Function Expression Alternative 
splicing 
2 
7 
8 
9 
10 
11 
12 
15 
17 
18 
19 
20 
21 
22 
23 
28 
 
29 
30 
33 
Sperm/egg binding/fusion 
 
Sheddase 
Sheddase, cell migration 
Sheddase, cell fate dtermination 
Putative tumour repressor 
Sheddase, myoblast fusion 
Cell/cell binding 
Sheddase 
 
Sheddase, dendritic cell 
development 
 
 
 
Cell adhesion/neural development 
Immune surveillance 
 
 
Genetically linked to asthma 
Testis 
Epididymis 
Granulocytes/monocytes 
Somatic 
Somatic 
Brain 
Somatic 
Somatic 
Somatic 
Testis 
Somatic 
Testis 
Testis 
Brain 
Brain 
Epididymis, lung, 
lymphocytes 
Testis 
Testis 
somatic 
 
 
 
FL,S 
L,S 
 
L,S 
 
 
 
 
 
 
γ,δ,ε 
 
M,S 
 
α,β,γ 
α,β 
 
In other cases, alternative splicing produces proteins with markedly different activity. 
For example, ADAM12 has two splice forms: one called L, that produces a membrane-
bound protein, the other called S, the secreted form (24). Removal of the cytoplasmic 
domain of ADAM12-L blocks retention and leads to cell surface accumulation, 
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suggesting the presence of retention signal within a region composed of the 
transmembrane domain and cytoplasmic tail (28). Because ADAMA12 is 
overexpressed during pregnancy, it is possible that ADAM12-S is responsible for 
increasing the pool of insulin-like growth factor (IGF) in the bloodstream during 
pregnancy through insulin-like growth factor-binding protein (IGFBP) proteolysis (29). 
Murine ADAM28 may have three forms, two larger ones predicted to encode 
membrane-anchored proteins and expressed in the epididymis and lung, as well as a 
smaller one predicted to encode a secreted protein with testis-specific expression 
(30,31). Human ADAM28 has two splice variants. The secreted form is preferentially 
expressed in the spleen, whereas the membrane-bound form is lymph node specific 
(26). ADAM9 and ADAM10 are also alternatively spliced and have both secreted and 
membrane-associated forms (33,32). There is evidence that ADAM11 and ADAM33 
genes also produce alternatively spliced products (34,35), but no functional relevance 
has been reported yet.  
ADAM15 was identified in a human breast cancer cell line (36), also it found in human 
aortic smooth muscle cells and umbilical vein endothelial cells in culture; furthermore, 
it is expressed in developing lesions of atherosclerosis, but not in normal vessels, 
suggesting that it may play a role in the pathogenesis of atherosclerosis (37). 
 
2.4 Subcellular localisation 
 
The prevailing data indicate that ADAM proteins are probably synthesized in the rough 
endoplasmic reticulum and mature in a late Golgi compartment (28,38,39,40). 
Maturation involves the removal of the prodomain from the ADAM precursor protein, 
which is thought to make the ADAMs metalloprotease competent. It appears that the 
bulk of the ADAM protein resides in a region near the nucleus, in some cases co-
localizing with the Golgi compartment (38,41,42). In many cases (e.g., ADAMs 8, 9, 
10, 15, 17, and 28), the cell surface form appears to be processed and is catalytically 
active (47,4,37,41,39,40). Several ADAM family members may be active 
intracellularly. The metalloprotease activity of ADAMs 10, 17, and 19 can occur within 
intracellular compartments (41,42,43,44). Such differences in subcellular localisation 
and according function may ultimately depend on the cell type, the ADAM protein and 
the substrate involved.  
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2.5 Functions of ADAM domains 
 
All of the deduced amino acid (aa) sequences of ADAMs predicted multi-domain 
structures. A signal peptide at the N-terminus targets protein for the secretory pathway 
and is removed prior to secretion from the cell or anchoring on the cell surface starting 
with the pro-domain, ADAM proteins contain between 800 and 1200 aa residues. The 
metalloprotease domain of ADAMs consists of about 200 aa. ADAMs containing a 
metalloproteinase domain are produced as zymogens. This is the result of formation of 
an intramolecular complex between a single cysteine residue in its propeptide and the 
essential Zinc ion in the catalytic domain, a complex that blocks the active site. Some 
ADAMs have a putative fusion domain in their cysteine-rich domains (1) or instead of 
the C-terminal domains thrombospondin (TS) motif (45).  
 
2.5.1. The Prodomain 
The N terminus of ADAMs contains a prodomain that functions in ADAMs maturation. 
The latent proteins can be activated by association of the cysteine complex followed by 
a conformational changes or enzymatic cleavage of the prodomain. This activation 
mechanism is called the “cysteine switch” (46). The prodomain consists of about 200 
residues that separate from the metalloprotease domain by one or more furin cleavage 
sites. Furin or furin-like proprotein convertases can cleave the prodomain from several 
ADAM precursors including 8, 9, 12, 15 and ADAMTs1 (47,39,48,38,45). This process 
does not seem to depend on the proteolytic activity of these ADAMs because the 
mutation of the catalytic Glu residue does not prevent removal of the prodomain. The 
cysteine switch motif in ADAMs may play a similar role during ADAM biosynthesis, 
preventing them from autocatalysis and self-destruction. This concept is supported by 
the observations that the prodomain of ADAM17 and ADAM12 both acts as inhibitors 
of the catalytic domain and are required for secretion of functional proteases (49,48). 
Pharamacological inhibitors of the early secretory pathway like brefeldin A and 
monensin block the processing of ADAM9 and ADAM15, thus positioning the location 
of ADAMs processing and activation at the trans-Golgi network (38,39). This location 
is consistent with the localisation of furin and other proprotein convertases (PCs). PCs 
cleave the prodomain from the rest of the protein at a conserved Rx(R/K)R motif, 
effectively releasing the prodomain and switching the Zinc coordination to the 
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metalloproteases domain, thereby making it available for catalytic activity. This 
mechanism is supported by various studies: 
1) Furin cleaves ADAM15 in vitro (38). 
2) Overexpression of PCs and furin increases the amount of processed ADAM10 in 
vivo and processing is blocked by the addition of a peptide analogue of the PC cleavage 
site (50). 
3) Mutation of PC cleavage sites blocks the processing of ADAM10, ADAM12, and 
ADAM19 to their mature active forms (45,50,42). These data indicate that, in vivo 
cleavage of the prodomain is a prerequisite for the generation of an active protease. 
Further support comes from the observation that, in vitro, the inhibitory effect of a PC 
cleavage site mutation is overcome by treatment with NEM, a sulfhydryl reactive 
compound that alkylates the cysteine residue, thereby switching the coordination of 
Zinc to the active site of the metalloprotease and bypassing the cleavage dependence of 
protease activation (48). Mutation of the cysteine residue in the prodomain of 
ADAM12 to alanine or histidine also leads to protease activation independently of 
prodomain cleavage (48,51). Finally, the application of cysteine switch peptides to cells 
inhibits ADAM9 and ADAM17 processing, presumably because the peptide competes 
for Zinc coordination in trans (39). There are cases in which ADAMs may undergo 
autocatalytic activation. This is most clearly shown for ADAM8 and ADAM28, in 
which activity-blocking mutations in the metalloprotease domains produces only the 
precursors form of the protein in transfected cells (30,47). 
The secondary function of the prodomain is to chaperone the proper folding of 
ADAMs, particularly the metalloprotease domain. This has been suggested by many 
studies showing that removal of the prodomain of ADAM17 generates a protease-
inactive protein (49). Similarly, ADAM10 construct lacking its prodomain is 
catalytically inactive in vivo. But co-transfection of this form together with a construct 
expressing just the prodomain of ADAM10 generates protease activity (50). 
Additionally, a form of ADAM12-S lacking a prodomain, unlike wild-type protein, is 
not secreted from the cell, but instead remains in the early endoplasmic reticulum (ER) 
system (48). Hence, the prodomain appears to be necessary for maintaining the latency 
of these enzymes, and it assists in the proper folding of ADAMs and in the proper 
transit of ADAMs throughout the secretory pathway. 
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2.5.2. The disintegrin domain  
The disintegrin domain is named for its presence in the snake venom metalloproteases 
(SVMPs), its blocks platelets association with their natural ligands and aggregation at 
the wound site. This disintegrin-mediated interaction of SVMPs along with the 
breakdown of the basement membrane components by their metalloprotease activity 
leads to the severe haemorrhaging caused by bites from snakes harbouring these toxins.  
It has had been proposed that the disintegrin-like domains in ADAMs, in contrast to the 
SVMPs, may promote cell-cell interactions since they are membrane-anchored proteins 
(3). 
The disintegrin domain of ADAMs consists of 60 to 90 aa with 6 to 15 Cys residues 
showing sequence similarity to the disintegrins generated from reprolysin precursors 
and snake venom. Like fibronectin, ADAM15 has an RGD consensus sequence within 
a 13 amino acid stretch called the disintegrin loop, which projects from the surface of 
the protein and confers binding to the platelet integrin αIIbβ3 and αvbβ3 and inhibit 
platelet aggregation (36,52).  
Specific interaction of the disintegrin domain of human ADAM15 with integrinαvβ3 is 
RGD-dependent, indicating that this domain functions as an adhesion molecule and 
may be involved in αvβ3-mediated cell-cell interaction (52). Only human ADAM15 
contains RGD sequence in the disintegrin domain. Nevertheless some ADAM proteins 
can still bind to integrins. For example, ADAM2 binds through its disintegrin domain 
to the α6β1 integrin which in turn interacts with the tetraspan protein CD9; this process 
is important in sperm passage into oviducts and sperm-egg interactions (53). In addition 
to ADAM15, ADAM12 also binds to integrin α9β1 in an RGD-independent manner and 
this binding supports cell-cell interaction (54).  
A short aa sequence (lacking any RGD's motif) of the disintegrin loop in ADAM23 
mediates the interaction between ADAM23 and αvβ3 integrin, indicating that ADAM23 
may be important in αvβ3-mediated cell-cell interactions occurring in normal and 
pathological processes (55). Some other members contain putative tripeptide binding 
sequences that have another negatively charged residue, (glutamic acid, E) in place of 
other aspartic acid (D). This negatively charged residue may be critical for function as 
an integrin ligand (15), others showed interaction of the disintegrin domain with zona 
pellucida of the egg, where no integrin exist (56). The ADAMs also contain an adjacent 
cysteine carboxyl-terminal to the tripeptide. It was suggested that disintegrin-like 
domains that contain this extra cysteine are functional adhesion molecules (15). Not all 
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ADAMs have highly conserved amino acids in their predicted binding loop (25). By 
considering the metalloprotease function, one possibility is that the disintegrin domain 
might be used to target the metalloprotease to another cell via an integrin. Alternatively, 
the disintegrin domain in combination with other domains such as the EGF repeat or 
the cysteine-rich region might increase the efficiency of the protease by binding to the 
substrate (12). 
Many ADAMs share a sequence (Rx6DEVF) in the disintegrin domain, when mutated 
it prevents the association with α9β1 integrins (57). Consistent with this, several 
ADAMs except ADAM10 and ADAM17 can bind to α9β1 (57). ADAMs can also 
associate with other integrin receptors. For example, ADAM28 binds to α4β1, ADAM15 
associates with αVβ3 and α5β1, and ADAM2 associate with α6β1 (53,58). 
 
2.5.3 The cysteine-rich and EGF-like domains  
Structurally, Cys-rich and EGF-like domains consist of about 160 aa with 10 to 14 Cys 
residues and about 40 aa with 6 Cys residues, respectively. There are some speculations 
that it plays an important role in the presentation of the disintegrin-like domain or 
perhaps is involved in protein-protein interactions (16). In some ADAMs this domain 
contains a putative fusion peptide which may promote membrane fusion (1). A few 
members of the ADAM family (human ADAM 1, 3, 12-S, and 12-L) have been shown 
to be implicated in cell-cell fusion (20,1,59,60,24). 
The protein-protein interactions mediated by the cysteine-rich region could in turn 
warrant the correct targeting and efficient transport of the ADAMs and also regulate 
ADAMs biological activities on the cell surface. This concept is supported by the 
following observations: 1) The Cys-rich domain of the TACE may play a role in the 
release of the prodomain and may be required for the shedding of interleukin-1 receptor 
type II (49,61). 2) The secreted ADAM12, which is highly expressed in placental 
tissues, binds to (IGFBP-3) through its Cys-rich domain and has IGFBP-3 protease 
activity (29). Within the Cys-rich domain of ADAM 1, 9, 11 12 and 14, there is a 
hydrophobic stretch of about 23 aa that has been termed as the potential fusion peptide 
because its predicted secondary structure and sequences are very similar to that of viral 
fusion protein (3). 
3) Perhaps the most compelling piece of data concerning a cysteine-rich domain-
specific function is that it acts as a ligand for the cell-adhesion molecule syndecan. This 
was first discovered in a study showing that the cysteine-rich domain of ADAM12 
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supports the in vitro binding of several different tumour cell lines, as well as a variety 
of non tumorigenic cells of bone and muscle origin through the interaction with cell 
surface heparin-sulphate proteoglycans (62,63). 
  
2.5. 4 The cytoplasmic tail  
This domain contains specialised motifs that have been postulated to be involved in the 
inside-out regulation of metalloprotease activity, the outside-in regulation of cell 
signaling, and/or the control of maturation and subcellular localization.  
The cytosolic portion of ADAMs is variable in length (between 40 to 250 aa). Due to 
its considerable size and noticeable motifs, the cytosolic domain of ADAMs may 
transmit signals between the interior and exterior of cells. Some ADAMs have 
relatively long cytoplasmic tails (human ADAMs 8, 9, 12-L, 15, and 22). These 
domains have unusual amino acid compositions; many are rich in serine, glutamic acid, 
and/or lysine. Surprisingly, they do not share sequence similarity with each other. Some 
ADAMs show cytoplasmic sequences rich in proline residues, which exhibit a 
conserved potential SH3 ligand domain RPXPXXP. There is evidence that these tails 
might contain binding sites for cytoskeletal-associated proteins and/or the SH3 domain 
of the protein tyrosine kinase Src (64,3). The membrane proximal region of the tail of 
ADAM9 associates with the catalytic domain of protein kinase C (PKCδ) (65).  
The cytosolic and TM domains of ADAM12 also contain a signal for retention in the 
trans-Golgi network (28). Similar signals may also be present in other ADAMs, such as 
ADAM15, that have been shown to reside at intracellular compartments in addition to 
the cell surface (38). ADAM15 has an extensive array of protein-protein interaction 
sites, including eight possible SH3-binding domains and four potential sites for tyrosine 
phosphorylation. ADAM15 has been reported to associates with a number of different 
proteins including adaptors (endophilin I, SH3PX1, and Grb2), and three Src family 
tyrosine kinases (Src, Lck, and Hck). Most of these associations have only been 
reported in vitro, although an in vivo association between ADAM15 and Lck was 
observed in Jurkat cells (66,67).  
ADAM12 has 10 possible SH3-binding domains and two potential sites for tyrosine 
phosphorylation. Like ADAM15, ADAM12 has also been reported to associate with 
Src, the related Kinase Yes, and Grb2 (68,69). In C2C12 myoblasts, this is mediated by 
the SH3 domain of Src and most membrane proximal of the proline motifs in 
ADAM12. ADAM12 is also a substrate for Src at its C-terminal tyrosine residue (70). 
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ADAM12 also associates with α-actinin-1 and 2, through interaction of either the 
spectrin-like repeats or the C-terminal EF hand containing region of α-actinin with the 
membrane proximal portion of the tail of ADAM12 (71). ADAM9 contains two 
potential SH3 ligand domains and showed binding to Src SH3 domains, but not Ab1 
SH3 domains in vitro (64). ADAM8 (MS2) also contains potential SH3 binding 
sequences (72). For these reasons, ADAMs may be involved in signal transduction. 
Furthermore, ADAMs may send signals by binding to integrins or other receptors, and 
thus the possibility of bidirectional signaling exists. 
 
2.6 Biological functions of ADAMs  
 
ADAMs were first discovered to be involved in fertilization. The fertilization and 
certain later stages in mammalian embryonic development require fusion between 
membranes of individual cells. The role of the guinea pig sperm surface protein fertilin 
in sperm-egg fusion was first investigated by Myles et al (1994). During biosynthesis in 
the testis, α and β subunits of fertilin assemble a noncovalently bound protein complex 
that is processed in at least two steps. This complex seems to be involved in sperm-egg 
membrane binding and fusion for several reasons:  
1) Monoclonal antibodies against fertilin can inhibit sperm-egg fusion (73). 2) Peptides 
corresponding to the predicted integrin-binding domain of fertilin inhibit sperm-egg 
fusion in guinea pig (59) and in mouse (74,60).  
Additional ADAMs have been found in the testis. For example, mRNAs encoding 
ADAM3-ADAM7 (3,75), ADAM11 (22), ADAM20 and ADAM21 (76) are expressed 
in spermatogenic cells. Moreover, there is some evidence that ADAM3 (cyritestin) in 
mouse may play a significant role in fertilization since cyritestin deficient mice are 
infertile (56). Using synthetic peptides it was shown that ADAM11 from Xenopus is 
implicated in fertilization (21).  
Several ADAMs are expressed in both adult and developing muscle cells: ADAM1 
(fertilin α), ADAM4, ADAM9 (meltrin γ), ADAM10, ADAM12 (meltrin α), 
ADAM13, ADAM15, and ADAM19 (meltrin β) (3,22,77). Therefore, they are 
suggested to participate in the cell-matrix and cell-cell interaction events that culminate 
in myoblast fusion. Skeletal muscle development involves the formation of 
multinucleated myotubes. Yagami-Hirosama and coworkers (1995) have shown that 
mouse ADAM12 is required for myotube formation (78). This function is also true for 
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the human ADAM12 (24). Some ADAMs are active via their metalloprotease domain. 
Human ADAM17 (TACE) is responsible for the release of the membrane-anchored 
cytokine tumour necrosis factor-α (TNF-α) from the plasma membrane, an important 
cytokine involved in inflammation (4,79). Also it processes the extracellular portion of 
NOTCH1 receptor (80). ADAM9 cleaves the insulin β chain and several peptides (39), 
ADAM9, 10 and 17 are also potential α-secretases that can cleave amyloid precursor 
protein (APP) (82,81). Bovine and human ADAM10 also able to process pro-TNF-α 
and type IV collagen (83,14). Since ADAM10 and ADAM17 are able to cleave the 
active ectodomain TNF-α from its membrane-anchored precursor, these molecules are 
believed to play a critical role in the control of this shedding process. In Drosophila, 
ADAM10 (Kuzbanian) is responsible for cleavage of the extracellular domain of 
NOTCH, which can explain how ADAM10 functions in lateral inhibition since 
NOTCH is a cell surface receptor that is involved in transmitting the signal for lateral 
inhibition (6). Engineered mice lacking either ADAM2 or ADAM3 were viable and 
healthy with normal development, although male mice were infertile (84,85). Mice 
harbouring a germ-line mutation in the metalloprotease domain of ADAM17 exhibit 
perinatal lethality (4,86). The more obvious phenotype defects in newborns include 
open eyelids, stunted vibrissae, and wavy hair. Histological studies of mutant foetuses 
reveal defects in epithelial maturation and organization that impairs the development of 
the digestive, respiratory, and hormonal systems (86). A gene-trapping analysis of 
murine genes involved in brain-wiring patterns revealed that homozygous deletion of 
ADAM23 results in tremor and ataxia (87). ADAM10-deficient mice die by day 9.5 of 
embryogenesis with pronounced defects in the neural and cardiovascular systems (88).  
ADAMs may also participate in the degradation of the ECM. Human ADAM12 has 
been demonstrated to bind to α2-macroglobulin (51).  
   
2.7 Inhibitors of metalloproteases 
 
Inhibitors of ADAMs metalloprotease activity fall into four broad classes: 1) Inhibit by 
denaturation; 2) Inhibit by Zn-chelating; 3) Small molecule inhibitors of catalysis; 4) 
Proteinacious inhibitors called tissue inhibitors of metalloproteases (TIMPS). The first 
two categories represent nonselective inhibitors such as a reducing agents or Zinc 
chelating agents. The third class arose from efforts to develop inhibitors of both MMPs 
and ADAMs, and comprise hydroxamate-based inhibitors that bind competitively to the 
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active site. The crystal structure of ADAM17 bound to a compound called IC-3 
suggests that hydroxamate inhibitors replace Zn-coordinating water molecules in the 
active site (19). One subset of hydroxamate-based inhibitors, which includes batimastat 
and marimastat, were designed to mimic the cleavage site of collagen, an MMP 
substrate. Other hydroxamate inhibitors include synthetic side chains that maximize fit 
into the catalytic site. These small molecule inhibitors are not always selective for 
MMPs. Batimastat and Ro-31-9790 inhibit ADAM17 better than several MMPs 
(89,90). TIMPs are endogenous regulators of MMPs (91). There are four known TIMPs 
in vertebrates, all of which exhibit high potency for MMP inhibition. The N-terminal 
domain of TIMPs fits like a wedge into the catalytic site of MMPs, whereas the C-
terminal domain probably imparts binding specificity. TIMPs are not totally selective 
for MMPs. TIMP-3 also inhibits ADAM17 (90) and ADAM12 (92). ADAM10 is 
inhibited by both TIMP-1 and TIMP-3 (90). Several ADAMs are sensitive to TIMP3. 
Processing myelin basic protein by ADAM8 and ADAM9 is not inhibited by any TIMP 
(90).  
 
2.8 Expression, structure, function of ADAM8 (CD156) 
 
 ADAM8 (also known as CD156) is expressed mainly in cells of the immune system, 
particularly monocytes and granulocytes (72). ADAM8 is also highly expressed in 
eosinophils, one of the most important effector cell type at the site of inflammation in 
allergic asthma. Furthermore, its expression has been shown to be inducible by 
lipopolysaccharide (LPS) and γ-interferon (93) and by TNFα in the central nervous 
system (94). ADAM8 has also been shown to be a novel osteoclast-stimulating factor, 
induced during osteoclast differentiation from monocytic precursors (95).  
Human ADAM8 cDNA was cloned from the human monocytic cell line THP-1 and 
granulocyte cDNA libraries. The cloned ADAM8 cDNA contained an open reading 
frame encoding 824 aa (96). The predicted protein sequences contained a 16 aa signal 
peptide, 637 aa external region, 25 aa transmembrane region and 146 aa cytoplasmic 
region. Four of the five potential N-linked glycosylation sites were conserved between 
the human and murine sequences. All the cysteine residues present in the ADAM8 
extracellular domain, except the one at position 33, are also found in mADAM8. The 
predicted amino acid sequences of ADAM8 shows a significant homology with 
sequence of SVMPs (72,93,96). 
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 Fourie et al., (2003) showed that ADAM8 is able to cleave membrane-bound CD23, 
the low affinity IgE receptor in transfected and human macrophage cell line. Release of 
soluble CD23 requires proteolytically active ADAM8, and physical association of 
ADAM8 was observed with the membrane-bound form of CD23. CD72 ligand and 
CD40 ligand were resistant to cleavage by ADAM8. Recombinant ADAM8 was able to 
shed endogenously expressed CD23 from U937 cells, but soluble ADAM17 was not 
effective (97). The similarity is observed in the extracellular region, which can be 
divided into two domains: the N-terminal sequences spanning residues 192-406 and the 
C-terminal sequences residues 407-496. A highly conserved motif, 
HEXGHXLGXXHD and a β-turn structure (Met-turn) found in are located a positions 
334 to 345. These structures would contribute to Zinc binding and catalysis. In addition, 
ADAM8 contains a pro-metalloprotease domain (N-terminal proximal to 
metalloprotease domain) and a cysteine-rich domain (C-terminal to the disintegrin 
domain) in which an epidermal growth factor (EGF)-like structure is contained (74,93). 
When ADAM8 is activated, a similar mechanism might be involved in the removal of 
the pro-metalloprotease domain by furin-like enzyme (47). ADAM8 lacks the RGD 
sequence that functions typically as a ligand for integrin. Instead, substitution by 
hydrophilic residues and the 13th cysteine might be involved in adhesion. The 
cytoplasmic region of ADAM8 is relatively long among the ADAM family proteins 
and is rich in proline; it contains SH3 and the Ab1 SH3 consensus sequences RPPPAPP 
and PXXXPPXPP, indicating a role in signal transduction as suggested for ADAM9 
(64). A transgenic mouse line has been created, expressing the extracellular region of 
ADAM8 in liver and kidneys under the control of α1 anti-trypsin promoter. Transgenic 
animals demonstrated a significantly higher neutrophil infiltration when examined for 
oxazolone-mediated contact hypersensitivity, suggesting that ADAM8 plays a role in 
the degradation of the vascular basement membrane, or in the liberation of 
physiological active molecules from their precursors harboured in cell surface of 
leucocytes and endothelial cells (98). 
 
2.9 Low affinity IgE Fc receptor (CD23)   
 
The development of atopic diseases is linked to increased levels of IgE, the antibody 
responsible for type I allergic hypersensitivity reactions (99). IgE binds to mast cells 
and basophils via the high affinity Fc receptor (FcεRI), and subsequent crosslinking of 
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FcεRI-bound IgE molecules by allergen leads to the release of mediators responsible 
for allergic tissue damage. In addition, IgE mediates allergen presentation through 
binding to FcεRI on Langerhans cells and monocytes, and to a much lesser extent 
through binding to its low affinity receptor (FcεRII), also known as CD23 (100). 
Considerable advances have been made in elucidating the effects of cytokines such as 
interleukin 4 (IL-4) and interleukin 13 (IL-13), as well as cell-surface molecules, for 
example CD40 and CD23, on IgE synthesis. Other work suggests some allergens, such 
as phospholipase A2 from bee venom (101) and Der p I from dust mite (101,102,103), 
in addition to act as immunogens, have the intrinsic ability to subvert the regulatory 
process controlling IgE synthesis, thereby favouring an allergic outcome.  
CD23 is type II membrane glycoprotein with a long C-terminal extracellular region 
(277 residues) and a short N-terminal intracytoplasmic tail (23 residues). The region 
homologous to C-type lectins spans from cysteine 163 to cysteine 282 and contains four 
highly conserved cysteines (positions 191, 259, 273, 282) and two partially (positions 
163 and 174). This structure might be involved in the formation of CD23 oligomers at 
the cell surface (104,120). In addition to the extracellular cleavage, a fraction of CD23 
is internalised and subsequently processed intracellularly to yield a 16kDa fragment. 
This endocytosis is enhanced by anti-CD23 monoclonal antibodies (122). Murine CD23 
has 2 instead of 1 N-linked glycosylation site, no DGR motif and 4 instead of 3 
consensus repeats (123).  
CD23 exists in two isoforms, a and b, CD23a is constitutively expressed only in normal 
B cell and EBV-transformed B cell lines, whereas CD23b is expressed on interleukin-4-
activated B cells, macrophages, eosinophils. In the mouse, only one FcεRIIa-like 
receptor has been reported. CD23 is a calcium-dependent type II integral membrane 
protein that belongs to the lectin family of adhesion molecules (104,105). On B cells, 
membrane CD23 and its soluble fragments have been shown to be involved in the 
regulation of IgE synthesis (107). 
Increased levels of CD23 have been reported in various chronic inflammatory diseases 
including systemic lupus erythematosus, inflammatory bowel disease, sjögren's 
syndrome, glomerulonephritis, and rheumatoid arthritis (107,108). It is expressed on a 
wide variety of haematopoeitic cell types, including B and T cells, FDC, monocytes, 
platelets, Langerhans cells, eosinophils and natural killer cells (109). By interacting 
with CD21, CD23 appears to mediate a variety of biological activities including cell-
cell adhesion, B-cell survival in germinal centres, histamine release from basophils and 
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regulation of IgE synthesis (106). CD23 is also involved in B-cell growth, pro-
thymocyte maturation, myeloid precursor proliferation, inhibition of macrophage 
migration and antigen presentation. 
CD23 was found to interact with the β2 integrins, CD11b and CD11c, on macrophages 
(110). CD23 acts both as a receptor and a ligand. As a receptor for IgE, CD23 is a focus 
for IgE immune complexes, leading to enhanced antigen presentation to T cells by 
dendritic cells (DC) and B cells. As an adhesion molecule, CD23 interacts with CD21 
to regulate IgE production and germinal centre B-cell survival (110).  
 
2.9.1 Structural features CD23 
The current structural model of CD23 predicts that three monomers interact with each 
other to form a functional trimer on the cell surface. This model is based on the noted 
heptad repeat pattern found in the stalk region of the molecule (111) and chemical 
cross-linking studies (112). The cleaved monomeric product interacts with only a single 
low affinity with IgE. Kelly et al (1998) found that a soluble CD23 oligomer with high 
affinity/avidity for IgE could be produced by attachment of modified leucine zipper to 
the amino terminus of the stalk region of CD23 (113,121). 
 
2. 9.1.1 Leucine zipper Motif 
Human CD23 has a leucine-zipper sequence near the transmembrane domain of its 
extracellular region and makes an α-helical coiled coil stalk, which mediates the 
formation of trimers. This leucine-zipper structure has a seven-amino-acid motif 
beginning with Leu or Ile that is repeated five times in the case of human CD23. An α-
helical coiled-coil stalk will be a more convenient means of making polymer than an S-
S bridge. The formation of oligomeric structures of CD23 showing 45 and 200kDa 
molecules after cross-linking them through amino groups was exploited experimentally 
(114). The structural features are as follows: (1) the IgE-binding, C-type lectin domain; 
(2) the a and b forms of CD23 that differ in their cytoplasmic amino acid sequences, 
and the YSEI sequence; (3) the leucine-zipper structure; (4) the protease cleavage sites 
and soluble forms of CD23; (5) the reverse-RGD sequence near the C-terminus; (6) the 
‘RGD-binding inhibition peptide’ at the root of the N-linked carbohydrate chain. 
 
2.9.1.2 Cytoplasmic amino acid sequence  
CD23 exists as a single copy gene located on chromosome 19 (115,116). In human 
there are two subtypes FcεRIIa and FcεRIIb (CD23a, CD23b), differing only in their N-
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terminal cytoplasmic sequence. CD23a has a tyrosine in the cytoplasmic sequence, 
whereas CD23b does not. These species appear to be generated by different alternative 
RNA splicing (117,118). Tyrosine exists as a member of the YSEI sequence in human 
CD23a (YSGT in mouse). A characteristic stretch of four amino acid residues, which 
are thought to form a sharp turn in the polypeptide chain (YXRF), forming an essential 
part of the endocytosis signal. The amino acids at the RF position in YXRF have large 
side chains. From this point of view, YSEI in human CD23a fits into this category, i.e. 
as an endocytosis signal (119).  
 
2.9.2 Regulation of CD23 
With the cloning of both CD23 (104) and the primary cytokine responsible for the 
induction of isotype switching to IgE, namely IL-4 (124) came the realisation that IL-4 
also regulated CD23 levels (125). It had been found that IL-4 is not the only cytokine 
able to induce CD23 expression on B cells. IL-13 was found to induce CD23 
expression on B cells and the production of IgE and IgG4 in an IL-4 independent 
manner (101,126). In contrast, interferon (IFN)-γ is known to decrease both CD23 
expression and production of IgE and IgG4 induced by IL-4. Downregulation by IFN-γ 
occurs mainly via mRNA instability at the post-transcriptional level (127). The IL-4 
signals leading to CD23 gene activation are mediated via a protein kinase C-
independent pathway. Infection with Epstein-Barr virus (EBV) leads to some resistance 
to the downregulatory effects of dexamethasone on IL-4 induced CD23 expression 
(128). CD40 engagement synergizes with IL-4 to induce CD23 expression on mature 
peripheral B cells; some antibodies to CD40 can even induce CD23 expression in an 
IL-4 independent manner. CD23 can be expressed by pro-B cells after triggering of 
CD40 in the presence of IL-3 (129). Cognate interaction between T and B cells results 
in the upregulation of CD23 and this probably involves CD40-CD40L pairing because 
CD40 transfectants increase CD23 expression on B cells (130). Evidence about 
functional differences between the CD23 isoforms has been provided by studies on B 
chronic lymphocytic leukaemia (B-CLL) cells, in which regulation of CD23 expression 
is quite different from that in normal B cells (131). IFN-α and IL-2 selectivity 
upregulate CD23b and stimulate growth, in contrast, IL-4 and IFN-γ upregulate CD23a 
and have no growth-promoting activities, but rather suppress B-CLL apoptosis (106). 
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2.9.3 CD23 and IgE regulation 
 
2.9.3.1 Human  
Physical interaction between T and B cells is known to be required for IgE production; 
therefore, a possible role for CD23 in IgE regulation would be to enhance T-B cell 
interaction by interacting with CD21 (132). Certain mAbs to CD23 inhibit T-B cell 
conjugate formation in vitro and this inhibition is restricted mainly to CD4+ T cells 
which form conjugate with B cells (132). The CD20-mediated decrease of membrane 
CD23 expression which results from an increase in soluble CD23 was accompanied by 
decrease IL-4 induced IgE production suggesting a positive role for the membrane form 
rather than for soluble CD23 in human IgE regulation (133). The anti-CD21 mAb had a 
synergistic effect on the expression of productive ε transcript induced either by anti-
CD40 mAb or by T cells (134). Therefore, the CD23-CD21 interaction needs a co-
signal to bring about the class switching of B cells toward IgE production (134). 
Interestingly, the EBV peptide that inhibited CD23 binding to CD21 also inhibited IgE 
and IgG4 production induced by IL-4 (135). The other ligand, C3b, did not affect 
binding of CD23 to CD21 nor the production of IgE and IgG4. Allergen induces CD23 
expression on CD4+ T cells and CD21 expression on B cells in patients with allergic 
asthma. Cagro et al (1994) reported that interaction of B cells with CD23-transfected 
CHO cells resulted in decreased B cell proliferation and IgE production in vitro. Thus, 
proliferation decreased with increased expression of membrane CD23 (135). 
 
2.9.3.2 Mice 
Injection of IgE anti-hapten antibody into mice enhances subsequent antibody 
responses to haptned antigen; however, anti-CD23 antibodies can block this 
enhancement (136). Overexpression of either membrane CD23 or soluble CD23 (38 
kDa) did not alter lymphoid cell maturation. The CD23-deficient mice do not display 
IgE-dependent augmentation of an immune response. Inactivation of the CD23 gene 
does not modify the capacity of mice to develop IgE responses to Nippostrongylus 
brasiliensis (137,138). Moreover, membrane CD23 transgenic mice showed an 
impairment of IgE responses. In contrast, soluble-CD23 transgenic mice behaved like 
non-transgenic mice regarding IgE production (139), suggesting that, in the mouse 
system at least the soluble form of CD23 does not exhibit the same activity as the 
membrane form. Immunization of CD23 knockout mouse with thymus-dependent 
antigen resulted in an increase of IgE production, which was interpreted as evidence for 
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CD23 providing negative feedback regulation for IgE synthesis (138). CD23 also plays 
a key role in the production of polyclonal and antigen-specific IgE response in vivo in 
the rat (140). Serum IgE is suppressed in CD23-Tg mice where B cells and some T 
cells express high levels of CD23, suggesting that CD23 on B and T cells may cause 
this suppression (141). FDCs are irradiation resistant, express surface CD23, and 
deliver iccosomal Ag to B cells, led to reason that Tg FDC may be a critical cell. FDC 
that interface with B cells in the germinal centre are a candidate for explaining this 
CD23-mediated IgE suppression (141). 
 
2.10 Facilitated antigen presentation 
 
CD23a facilitates antigen presentation in murine and human B cells in vitro and in 
murine B cells in vivo. CD23 in human B cells mediates IgE-dependent Der p I allergen 
presentation to autologous Der p I-specific T cell clones in vitro (142). CD23 associates 
with the membrane of human B cells to HLA-DR, with which it undergoes endocytosis 
and cycling (143). The association may facilitate the transfer of peptides to the HLA-
DR in peptides-loading compartments of the cell and also adherence of B cells to T 
cells during antigen presentation. Antibodies against either CD23 or CD21 inhibit 
antigen presentation (144). Because antigen presentation by CD23 is isotype rather than 
antigen specific and delivers the antigens attached to IgE, it will promote immune 
responses to allergens (145). In the Th2 microenvironment of mucosal tissues, B cells 
switch to IgE and thereby amplify the pre-existing IgE response. Thus, IgE-dependent 
CD23-mediated antigen presentation to Th1 cells may exercise positive feedback 
control (146). Kehry et al (1989) demonstrated that CD23 on B cells could considerably 
augment the Ag presentation capacity of B lymphocytes (147). Squir et al (1994) 
further demonstrated that covalently linking Ag to anti-CD23 would augment the 
humoral response and proposed that this property of CD23 could be a useful vaccine 
strategy (148). Adoptively transferred CD23+ lymphocytes into CD23-/- mice 
demonstrate that CD23 expression in B lymphocytes is necessary for the IgE/Ag/ 
CD23-mediated enhancement of the IgG response (149). 
Anti-CD23 and IgE monoclonal antibodies inhibit presentation of alloantigen in the 
mixed lymphocyte reaction (150). 
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2.11 Ectodomain shedding of CD23 
  
CD23b expressed on the cell surface of human B-cells and monocytes in response to 
interleukin-4 and processed concomitantly to give multiple defined soluble fragments 
(sCD23) (151). The fragments are biologically active as immunostimulatory cytokines 
and are also involved in regulation of IgE synthesis (152). ''CD23 processing enzyme 
belongs to the metalloprotease class, as it was demonstrated by inhibition studies using 
1,10-phenanthroline and imidazole. Inhibition of CD23 cleavage by batimastat suggests 
that the processing enzyme is in the family of enzymes inhibited by hydroxamic acid'' 
(153). These enzymes are disintegrin-metalloproteases with Zn2+-binding domains high 
sequence similarity to that of MMPs (154). Inhibition of the metalloprotease activity 
prevents the formation of the 37 and 33kDa sCD23 fragments (153,154). The major 
form of CD23 that accumulates in serum is the 25kDa fragment (155). Surface CD23 is 
cleaved into soluble fragments ranging in size from 37 to 16kDa. The rate of cleavage 
is reduced by IgE and anti-CD23 antibodies and increased by agents which prevent 
glycosylation of CD23 (156). 
Human CD23 can be cleaved at four points, releasing soluble forms of CD23 with sizes 
of 25, 27-29, and 33kDa (153,157). The release of 33kDa soluble CD23 from cell 
membrane is mediated by a membrane bound metalloprotease (153). From the primary 
structure of CD23, the cleavage site of releases 33kDa is expected to be the carboxyl 
side of Arg, and thus it is expected to be a trypsin-like protease whose substrate 
specificity is the carboxyl side of Arg or Lys. Soluble CD23 of 25-27kDa is also 
cleaved by the same or similar proteases, as judged by sequence specificity: Lys 147 
and Arg 149 are reported to be the cleavage sites for this fragment (153,156,157). Gut 
et al (1998) reported that ATP induces the shedding of CD23 from lymphocytes. It is 
likely that many different proteases are involved in the cleavage of CD23 (158).  
Hewitt et al (1995) have reported that the cysteine protease from the house dust mite 
cleaves CD23. The major house dust mite allergen, Der p I, has a high similarity with 
animal and plant cysteine protease (159). On the other hand, anti-CD20 or anti-CD40 
causes an increase in sCD23 cleavage (160). This illustrates that T-B cell cooperation 
plays a role in sCD23 release. In contrast, the antibody that recognizes the lectin 
domain, as well as IgE, protects CD23 from proteolytic cleavage and stimulates its 
endocytosis (161).  
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When CD23 is not occupied by IgE, it undergoes proteolytic cleavage releasing soluble 
CD23 (sCD23) fragments of different molecular size, which have been shown to either 
upregulate (>25kDa fragment) or downregulate (16kDa fragments) IgE synthesis 
(163).The initial cleavage of the membrane-associated CD23 stalk to generate the 
largest (37kDa) sCD23 from the 45kDa parent polypeptide chain is affected by a 
membrane-bound metalloprotease (153). The other proteases attack sCD23 at specific 
sites in the residual stalk sequence, terminating in formation of the 16kDa fragment, 
which is also the product of digestion by the house dust mit, Dermatophagoides 
pteronyssin, Der p I protease (164). CD23 and 16kDa sCD23 may have opposite effects 
on the regulation of IgE synthesis (165). Endogenous or exogenous proteases that 
cleave CD23 from the surface of B cells would potentially disrupt the IgE regulatory 
mechanism, which in some cases would leads to excessive IgE synthesis. It has been 
shown that Der p I cleaves CD23 from the surface of cultured human B cells (166). A 
more detailed investigation of the CD23 cleavage by Der P I has used both a 
recombinant 40 kDa protein, presenting the entire extracellular portion of human CD23. 
This found that Der p I cleaves CD23 at two sites (Ser155-Ser156 and Glu298-Ser299) 
to produce a 143 residue 17kDa fragment, containing the lectin domain and part of the 
C-terminal tail (164,166). This 17kDa fragment (amino acids 156-298) contains the 
minimum structural requirement for binding both IgE and to CD21 (also known as 
CR2), and as such should be capable of modulating IgE synthesis (164).  
Figure 2. Is a schematic presentation of human CD23. Region 4 contains the potential 
cleavage sites by the metalloproteases (162).  
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Figure 2. Schematic presentation of human CD23. Region 4 includes the potential 
cleavage positions by the metalloproteases (162).  
 
2.12 The Integrins Family 
 
The term “integrins” was coined to reflect the capacity of members of this family to 
integrate the extracellular and intracellular environment. Integrin-mediated interactions 
are vital to the maintenance of normal cell function because of their ability to mediate 
inside-out (intracellular to extracellular) and outside-in (extracellular to intracellular) 
signalling (167).                       
Integrins are a ubiquitously synthesized family of heterodimeric receptors that mediate 
cell adhesion to extracellular matrix and plasma proteins (such as fibronectin, 
vitronectin, collagens, laminins, osteonectin, thrombospondin, fibrinogen, von 
Willebrand factor, coagulation factor X and complement iC3b) as well as cellular 
counter receptors (VCAM-1, MAdCAM-1, ICAM-1, -2, -3) (168). Up to date there are 
18 different α subunits and 8 β subunits have been identified in vertebrates. These 
combine to make 24 different α/β combinations, all with different ligand specificities. 
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Two integrin subfamilies recognize short peptide sequences that include an Asp residue. 
One of these belongs to α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and αIIbβ3 integrins, also 
known as RGD-binding integrins (169).   
They consist of two distinct, associated subunits (noncovalent heterodimers), where 
each subunit (α, β) consists of a single transmembrane domain, a large extracellular 
domain of several hundred amino acids and typically, a small cytoplasmic domain of 
somewhere between 20-70 residues (169).  
Ligand binding initiates a process of ‘outside-in signaling’ that leads to downstream 
events, including the activation of focal adhesion kinase (FAK) and mitogen-activated 
protein (MAP) kinase (170). The interaction of both αIIb and β3 tails with various 
intracellular molecules induces a conformational change (affinity modulation) 
propagated to the ligand-binding site, that results in increased affinity for the ligand. 
This ‘inside-out’ signaling model helps to explain high-affinity binding of plasma 
fibrinogen to platelets activated in response to soluble stimuli (171). Because affinity  
modulation has been the most extensively studied model, ‘activation’ is often defined 
as an increase in integrin affinity for ligand, a broad definition define integrin activation 
as the increased ability to mediate cell adhesion and/or ligand binding. Although 
divalent cations are essential for integrin activation, the underlying mechanism has not 
been fully elucidated, and two different models have been proposed. In one model, 
divalent cations directly link ligands to integrins. Supporting evidence for this 
hypothesis came from the first crystal structure of an ‘I domain’, which is found in 
many α-subunits (172).   
For coordination of a magnesium ion, the αM I domain uses a DxSxS sequence. Such 
sequences called metal ion-dependent adhesion site (MIDAS) motif, together with an 
acidic residue likely provided by ligand (e.g L/I-E-T-P/S in ICAMs). Not all α-subunits 
contain I domain, but a MIDAS-like motif is present in all β-subunits and mediate 
ligand binding. On β3, the formation of a ternary complex between integrin, cation and 
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Figure 3. Tree of sequence similarity and ligand specificity of integrin α subunits (170). 
 
ligand accounts for initial integrin-ligand interaction, but following ligand binding, the 
cation is eventually displaced from the complex (172). According to the second model, 
divalent cations act indirectly by conformational changing the integrin-binding site, as 
suggested by the analysis of some CLIBS (cation-and-ligand-influences binding site) 
epitopes. Stimulatory cations (e.g. manganese ions) can induce the same conformation 
that is normally induced upon ligand binding, suggesting that cations regulate a 
conformational equilibrium between resting and active integrins. There is structural 
basis for Mn2+ binding to integrins because a novel Mn2+-binding site with micromolar 
affinity has been identified on the αM subunits and a homologous site in the β3 subunits 
(173). Mg2+-dependent conformational changes was described in the metal coordination 
site of the I-domain crystal in αM (174) and αL (175).  
 
2.13 RGD motif and its importance in integrin interaction 
 
All snake venom disintegrins contain an RGD integrin-binding motif within a large, 
flexible loop, this induce haemorrhage by antagonizing the pro-thrombotic platelet 
integrin αIIbβ3. Many other metalloproteases contain acidic motifs that might mediate 
integrin binding (176,177).  
Many physiological and non-physiological integrin ligands utilize RGD, LDV or related 
sequences as a key structural component of their receptor-binding domain (178). These 
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molecules include the disintegrin family derived from viper venoms and a neurotoxin-
related molecule Dendroaspin (Mambin) isolated from the venom of the Jamesons 
mamba (Dendroaspis jamesonii) (179,180). The disintegrin structural scaffold seems to 
be highly suited for the presentation of integrin recognition sequences as a replacement 
for the RGD sequence in the inhibitor from the venom of Calloselama rhodosma 
(Kirstin) with LDV-engendered binding activity specifically for integrin α4β1 (181). 
Furthermore the LDV sequence and αxβ2 recognition motif GPR have been located 
within a novel disintegrin-like domain present in the rotavirus capsid protein VP7 (182). 
Many studies have established an important function of amino acid residues 
immediately flanking the RGD sequence in regulating the specificity of the integrin-
ligand interaction (183,184). Scarborough and co-workers (1993) observed that 
disintegrins with an RGDW motif display a higher avidity for the integrin αIIbβ3, 
whereas disintegrins with an RGDN sequence interact more strongly with αvβ3 and α5β1 
integrins (185). Rahman and co-workers (1995) reported that structurally unrelated 
venom proteins (Kirstin and Dendroaspin) harbouring identical RGD flanking residues 
(PRGDMP) showed analogous inhibitory properties in platelet adhesion assays and 
could compete with one another in a simple linear competitive manner for binding to 
the αIIbβ3 complex (186).  In contrast, the platelet aggregation inhibitor from the venom 
of Trimerasurus elegans (Elegantin; ARGDNP), showed distinct inhibitory properties 
in platelet adhesion assays and was inhibited by kirstin in non-competitive manner. 
Definitive evidence for the regulatory function of the RGD-flanking residues was 
obtained by the introduction of both single and double amino acid substitutions around 
RGD sequence in Dendroaspin to the complimentary residues of Elegantin (187). That 
is, a single Met46→Asn substitution (PRGDMP→PRGDNP) produced a novel and 
potent inhibitory activity in Dendroaspin directed against platelet adhesion on 
fibronectin. Furthermore simultaneous Pro42→Ala and Met46→Asn substitutions 
(PRGDMP→ARGDNP) enhanced the inhibitory activity towards platelet adhesion on 
fibronectin and increased the affinity for the second class of binding site on the αIIbβ3 
complex proportionally. Rahman and co-workers (1998) addressed the role of the 
residues flanking the RGD sequence in the interaction with αIIbβ3 and α5β1 integrins. 
Elegantin molecules into which a Met residue was introduced in place of the Asn 
residue C-terminal to the RGD sequence showed 10-13 fold elevated inhibitory activity 
towards platelet adhesion on fibrinogen. Both PRGD and ARGD were strong inhibitors 
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of adhesion to fibrinogen which is due to markedly improved recognition of α5β1 
complex by the PRGD molecules (176). 
 
2.14 Interactions of ADAMs and integrins  
 
ADAMs are potential ligands for integrins due to the presence of identifiable integrin 
binding motifs within their disintegrin domain and by their homology to snake venom 
disintegrins which can bind to integrins like αIIbβ3 and αvβ3 (52,58). 
Human ADAM-15 (Metargidin) is the only ADAM that has an RGD motif in its 
disintegrin-like domain (58). Integrin α6β1 has been reported to interact with the 
disintegrin domains of fertilin α and β complex that has no RGD motif during 
fertilization (53). 
Zhang et al (1998) found that ADAM15 specifically interacts with αVβ3 but not with 
other tested integrins (α2β1, α3β1, α4β1, α5β1, α6β1, α6β4, αvβ1, αIIbβ3, and αLβ2). Mutation of 
the tripeptide RGD to SGA totally blocked binding of ADAM15 to αvβ3, suggesting that 
the ADAM15-αvβ3 interaction is RGD-dependent. When the sequence RPTRGD is 
mutated to NWKRGD, ADAM15 is recognized by both αIIbβ3 and αvβ3 in an RGD-
dependent manner (52), suggesting that the receptor binding specificity is mediated by 
the sequence flanking the RGD tripeptide. Nath et al (1999) showed that ADAM15 can 
bind to αvβ3 on monocytic cell line U937, and to α5β1 integrin on the T cell line, MOLT-
4 (58). 
Eto et al (2000) demonstrated a novel RGD-independent interaction of integrins to 
ADAMs. It was shown that ADAM disintegrin domains that lack an RGD motif (mouse 
ADAM15, human ADAM15 mutants, and human and mouse ADAM12) support cell 
adhesion to α9β1 in an RGD-independent manner. The cysteine-rich domain of 
ADAM12 has a putative fusion peptide and a short hydrophobic stretch. Therefore 
ADAM12/α9β1 interaction through the disintegrin domain in vivo may be involved in 
myogenesis (48,24).  
Thodeti et al (2003) demonstrate that ADAM12/syndcan-4 regulates cell spreading in a 
β1 integrin-dependent manner through PKCα and RhoA, which function in separate 
pathway (188) 
It is well established that short synthetic peptides containing the RGD integrin-binding 
motif can mimic the binding activity of integrin ligands. They can promote cell 
adhesion when immobilized onto a surface, and inhibit it when presented to cell in 
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solution. The functional RGD motif in integrin ligands is thought to exist in a 
favourable conformation at the apex of a long loop between two β strands. Hence, the 
affinity of cyclic peptides is several folds more than linear peptides. Also GRGDS 
partially inhibited binding whilst cyclic RGDC peptides completely inhibited binding of 
U937 cell to ADAM15 (58). Structural studies of RGD-containing domains, like the 
tenth type-III repeat from fibronectin domain, the disintegrin Echistatin and foot-and-
mouth disease virus (FMDV), reveal that the RGD sequence is present at the apex of a 
long flexible loop and thereby is accessible for high-affinity interactions with integrins 
(188). 
Bax et al (2004) demonstrated a functional interaction between ADAM17 and α5β1 
integrin in a trans orientation. Recombinant ADAM17 was found to support integrin 
α5β1-dependent attachment and spreading. ADAM17-integrin interactions were divalent 
cation-dependent, inhibited by synthetic RGD peptides, and mediated by the 
disintegrin/cysteine-rich domain region. Furthermore, ADAM17 and α5β1 were localised 
in membrane protrusions during Hela cell migration (176). 
Fertilin β utilizes an ECD sequence within its disintegrin domain to interact with the 
egg plasma membrane; the Asp is especially critical (168). Three of the five integrins 
implicated as receptors for ADAMs are members of the RGD-binding subfamily: αvβ3, 
αvβ5, and α5β1. These integrins interact with ADAM15, ADAM9, and ADAM23. 
ADAM9 and ADAM23 do not have RGD sequences in their disintegrin domains, but 
instead have ECD sequences. Another integrin of another subfamily, the α4/α9 integrins 
(α4β1, α9β1, and α4β7), recognize short peptide sequence that include an Asp residue. In 
the ligands for which the structure is known, the Asp residues are presented on 
protruding loops, similar to the presentation of the RGD tripeptide in fibronectin and 
disintegrins. Because α4β1 recognizes an Asp-containing sequence (IDs in VCAM-1) 
and this interaction is disrupted by an MLDG-containing peptide. Thus Zhu et al (2002) 
hypothesized that an MLDG-containing peptide might perturb the ECD-mediated 
interaction of fertilin β with sites on the egg membrane (168).  In addition, α9β1 interacts 
with sequences that are similar to the ECD in mouse fertilin β: RGDCD in human 
ADAM15, TDDCD in mouse ADAM12, and SGACD in a mutated form of human 
ADAM15 (54). VCAM-1 can be disrupted with the dimeric snake disintegrins EC3 and 
EC and with peptides containing the sequences MLDG (189,190).  
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3. The aim 
 
The family of ADAMs is growing rapidly. Because ADAM8 is not well characterized. 
The aim of this study is to cloned, expressed and characterized mouse and human 
ADAM8. After production and purification of ADAM8, bovine myelin basic protein 
was used substrate in order to monitor their activity and to compare their cleavage 
products. Human and mouse ADAM8 produced different product sizes. Then we used 
mouse ADAM8-Fc to raise antibodies. The both serum and affinity purified IgG anti 
mADAM8-Fc antibodies were suitable to detect both ADAMs, also applicable for 
western blot and FACS flow cytometry analysis. CD23 (low affinity IgE receptor 
FcεRII) is released from cell surface by metalloprotease. It has been shown to have a 
role in the human immune response, in particular in the regulation of IgE synthesis. 
Soluble fragments released, these fragments are biologically active and involved in the 
regulation of IgE synthesis. We investigated whether ADMA8 cleave ectodomain of 
CD23. Human ADAM8 produced 33kDa fragment, this fragment believed to be very 
important in allergic reaction. Furher more mADAM8-Fc and hADAM8-His66 cleaved 
peptides of the stalk region of the CD23 at identical sites. These peptides contain 
putative cleavage sites, and cleavage sites were identical with the predicted sites.   
Most ADAMs contain disintegrin domain, this domain believed to bind to the integrin 
subunits expressed by other cells. Some ADAMs have been shown to bind to integrins 
and involved in adhesion of cells. Therefore we used soluble hADAM8-His6 to find 
out whether it binds to integrin subunits. We found ADAM8 binds to various integrin 
subunits and strongest binding was with αLβ2.  Also we attempted to find out whether 
ADAM8 binding with integrin inhibited by using cyclic peptides against the 
protruding loop of the disintegrin domain of human ADAM8. Very weak inhibition 
observed.  
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4 Materlas and Methods 
 
 
4.1 Materials and Reagents Supplier 
 
 ECL- Filmes Amersham 
 Lumi Light (Plus) Roche 
 Pipettes Tips, Centrifuge tubes and culture tubes TPP 
 Plastic materials for cell culture Nunc, Greiner, TPP 
 Plasmid-DNA islolation Kit 
(Nucleo-spin plus “Nucleobond 500”) 
Macherey-Nagel    
 
 Protein Assay ESL Roche 
 RNA isolation Kit (RNAII) Macherey-Nagel 
 Protein A-Sepharose Pharmacia 
 Protran membrane (0.2µm)   Scleicher&Schuell     
Bioscience GmbH  
 Sterile filters Roth 
 Transfection reagent “Fugene” Roche 
 
4.2 Instruments 
 
 
 Autoclave   Technorama 
 Begasung incubator Steri-cult 2000    Forma Scientific 
 Balance A 120-S, L 610 D Sartorius 
 Blot shaker Heidolph Duomax 030 
 Blot washer   Edmund Buehler L2 
 Centrifuges:   
                   Cool centrifuge J2-21 (Rotors JA10, JA14, JA20)   Beckmann 
                   Centrifuge 5417C    Eppendorf 
                   Centrifuge 5415       Eppendorf 
                    Lab Centrifuge Allegra X-15R       Beckman Coulter 
 DryEase Mini-Gel Drying System Invitrogen 
 Electrophoresis Chamber DNA, SDS-PAGE     Workshop University      
of Bielefeld 
 ELISA Reader   DYNATECH 
 MR500  Flow Cytometry FACScalibur     Becton Dickinson 
 MALDI-TOF (Voyager DE) Applied Biosciences 
 Microscope TCS SP2     Leica 
 GeneAmp PCR System 9700 Perkin Elmer 
 pH-Meter Ph 540 GLP WTW 
 Photometer Ultrospec 3000   Pharmacia Biotech 
 Power supply units 2197 Power-Supply GPS 200/400   Phamacia Biotech 
 Pure water device ELGA STAT Elga 
 Safe bench Lamin-Air HBB 2472 Haereus 
 Scales A120-S, L 610 D   New Brunswick 
Scientific Co., Inc.  
Adolf Kühner AG           
 Thermomixer Comfort Eppendorf 
 UV transluminator Biometra TI 3 
 Ultrafiltration Membrane (0.2µm) Amicon 
 Vacuum drying centrifuge Speedvac Concentrator   Savant 
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 Wet-Blotting chamber Mini    BioRad 
 ZipTips Millipore 
 
4.3 Chemicals 
 
 
 Acetonitril    Merck 
 Acrylamide/Bisacrylamid solution (30%/0,8%)     Roth 
 Agarose    Roth 
 Ampicillin     Roth 
 Angiotensin I      Sigma 
 Bovine mylien Basic protein (bMBP) Upstate 
 Bradykinin   Sigma 
 G418    PAA 
 Gentamycin sulphate Serva 
 Glutamate   PAA 
 HEPES Roth 
 Hygromycine    PAA 
 Insulin Sigma 
 Insulin Chain β Sigma 
 Low molecular weight marker Pharmacia Bioscience 
 LMP Agarose FMC Bioproducts 
 Ni-NTA agarose Qiagen 
 Prestained protein ladder   MBI Fermentas GmbH 
 Proteinase inhbibtor mini cocktail Roche 
 Puromycin     Sigama 
 Pyruvate PAA 
 SDS (Sodium dodecyl sulphate) Serva 
 Skimmed milk (Sucofin) TSI-Trade service            
International 
 Tetracyclin Serva 
 TriFluoroactic acid   Solvary Gmbh 
 Triton X-100 Serva 
 Trypsin/EDTA solution PAA 
 Tween 20 Serva 
 
4.4 Buffers, Mediums and other solutions 
 
 
 Agar plates    LB medium 1.5% (w/v) Bacto-Agar,  after     
cooling the appropriate antibiotic was            
Added; 4˚C 
 Acrylamid solution   30% (w/v) Acrylamid; 0.8% (w/v)                  
Bisacrylamid; 4˚C 
 Anarapid   22% (v/v) Ethnol, 1% (v/v) Glycerol,              
1% Methanol, 1% Isopropanol                         
 6xHis tagged Proteins buffer 50mM NaH2PO4, 300mM NaCl, 250mM 
Imidazol                                                           
 Coomassie destain solution 45% (v/v) Methanol, 10% (v/v) Acetic acid    
 Coomassie G250 solution   0.5% Coomassie G250, 45% Methanol,          
10% Acetic acid 
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 CTAB solution    5% (w/v) Cetyl-trimethyl Ammonium 
bromide, 0.5M NaCl                                        
 DES-Medium Schneider medium, 10% (v/v) FCS                 
(heat inactivated) 
 
 DMEM (for Cos-1 and HEK293 EBNA)  DMEM essential medium, 30ml Goodies F,    
5ml Glutamate and 10% (v/v) FCS; 4˚C          
 DNA-loading buffer (10x)     30% (w/v) Ficoll, 0.05% (w/v)                        
Bromophenol blue, 0.05% (w/v)                      
Xylencyanol; 4˚C 
 Farme's Reducing solution 0.03M K3[Fe(CN)]6, Na2S2O35H2O 
 G418 stock solution   00mM pyruvate, essential and non essential    
amino acids, vitamins (PAA); -20˚C                
 Laemmli-sample buffer (2x)   100mM Tris-HCl pH 6.8,  200mM                 
2-mercaptoethanol, 20% (w/v) glycerol, 4% 
(w/v) SDS, 0.02% Bromophenol blue             
 LB-Medium 1.0% Bactotryptone, 0.5% yeast  extract,        
1% NaCl, 4˚C 
 LB-AMP-Medium LB-Medium, 50µg/ml Ampicillin 
 Lysis Buffer 25mM Tris-HCl pH 7.4, 150mM NaCl,           
1% (w/v) Triton X-100, “Complete Mini”       
protease inhibitor (Roche)                                
 PBS 137mM NaCl, 2.7mM KCl,                             
4.3mM Na2HPO4, 1.4mM KH2PO4 
 PBST   PBS 0.05% (w/v) Tween 20 
 Peptide Assay Buffer 100mM Tris, 100mM NaCl,                            
10mM CaCl2, 20µM ZnCl2 pH 7.4 
 Ponceau S solution   0.1% Ponceaue S, 5% (w/v) acetic acid           
(SIGMA) 
 Pro 293 A   Biowhittker 
 Puck's solution A 5.4mM KCl, 136mM NaCl, 4.1mM 
NaHCO3, 5.6mM D-Glucose, 2mM MgCl2,    
2mM MnCl2 pH 7.4 
 5x RT Buffer (Invitrogen) 250mM Tris-HCl pH 8.3, 15mM MgCl2, 
375mM KCl (-20˚C) 
 Ripa Buffer   158mM NaCl, 10mM Tris-HCl pH 7.4, 
5mM Na-EDTA, 10µM Na4P2O7, 10mM 
NaF, 1mM Na3VO4  
 RPMI RPMI 1640 essential medium, 10% (v/v) 
FCS (heat inactivated),  
pyruvate, L-glutamine 
 SDS-Electrophoresis buffer 25mM Tris, 192mM glycine,  
0.1% (w/v) SDS 
 STET buffer     50mM Tris-HCl pH  8.0, 8% (w/v) sucrose,    
50mM Na-EDTA, 0.1% (w/v) Triton X-100   
 TAE buffer 40mM Tris/acetic acid pH 7.8,                         
10mM NaOAc, 1mM Na-EDTA  
 TBS   25mM Tris/HCl pH 7.4, 137mM NaCl, 
2.7mM KCl 
 TBS-T TBS, 0.1% (v/v) Tween 20 
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 TE 10mM Tris-HCl pH 8.0, 1mM Na-EDTA 
 Tfb1 30mM KOAc, 50mM MnCl2, 10mM CaCl2, 
100mM KCl, 15% (v/v) glycerol, pH 6.0 
(acetic acid), steril filtered 
 Transfer buffer (wet blot) 1x 25mM Tris, 20mM glycine, 20% (v/v) 
methanol 
 Tyrod's Buffer 5mM Hepes pH7.4, 150mM NaCl, 2mM 
NaHCO3, 2.6mM KC2l, 5mM D-Glucose, 
1mM MgCl2, 1mM MnCl2, 1% BSA 
 
4.5     Bacterial strain  
 
Strain                                  Genotype                                                                Source 
                                     
XL1 blue                      recA1 endA1 gyrA96 thi-1 hsdR17 supE44                   Stratagene 
                                     relA1 lac [F' proAB laclqZ∆M15 Tn10 (Tet1)] 
 
 
4.6 Cell lines Description Source 
 
 COS-1 Transformed kidney fibroblast, established 
from CV-1 Simian cells (cercopithecus 
aethiops) which were transformed by an 
origin-defective mutant of SV-40, expression 
of large T-antigen allows episomal replication
of SV40 origin containing plasmids. 
ACC 63: DSMZ  
 CHO The CHO-K1 cell line was derived as a 
subclone from the parental CHO cell line 
initiated from a biopsy of an ovary of an adult
Chinese Hamster. Integrin expressing cells 
were provided by Dr.Y. Takada (The Scripps 
research institute, La Jolla, CA, USA) 
ATCC: CCL-61 
 P388D1 Adherent elliptical and round loosely  
adherent cells growing in monolayers murine 
monocytes-macrophages established from the 
ascites of a DBA/2 mouse with a lymphoid 
neoplasm  induced by methylcholanthrene 
and subsequently enriched for adherent 
(monocyte-macrophage) cells by selection 
(yielding this IL1- producing subclone); 
reported to produce IL-1 after stimulation 
with  LPS or PMA. 
DSMZ:  288 
 DES Drosophila S2 cells derived from primary 
culture of late stage Drosophila melanogaster
embryos. 
Invitrogen 
 HEK 293-EBNA1 Human embryonic kidney fibroblasts. 
Transformed with Adenovirus V DNA,  
stably expressing Eppstein  Barr Virus (EBV)
EBNA-1 gene controlled by CMV promoter. 
Allows episomal maintenance of EBV origin 
Invitrogen 
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containing plasmids.  
 IM-9 Derived from bone marrow removed from a 
female  patient with multiple myeloma. The 
cells have receptors for insulin, calcitonin  
and human growth hormone. They also 
exhibit surface markers and receptor sites 
characterised of B lymphocytes. The cell 
synthesise IgG at a rate of 2.4ug/1,000,000 
cells/day. This line has been shown to be an 
EBV-transformed B lymphoblastoid cell line. 
The cells are EBNA positive.  
ATCC: CCL-159 
 
 THP-1 Human monocytic leukaemia cell line, 
derived from the peripheral blood of a 1 year 
old male with acute monocytic leukaemia. 
They have Fc and C3b receptors and lack 
surface and cytoplasmic immunoglobulins. 
and can be differentiated into macrophage-
like cells using for example DMSO. 
ATCC: TIB-202 
 U937 The U-937 cell line was derived from 
malignant cells obtained from  the pleural 
effusion of a patient with histiocytic 
lymphoma. The cells are negative for 
immunoglobulin production and Epstein-Barr
virus expression. 
 
ATCC: CRL-1593.2
 
4.7 Antibodies 
 
  
 Antibody Description Source 
 Anti-human IgG-Fc Goat anti human IgG-Fc HRP Dianova 
 Anti-mADAM8   Goat anti mouse (mono) R&D Systems  
 Anti-hADAM8 Ectodomain Goat anti human (Poly)   R&D Systems 
 Anti-mADAM8-Fc Rabbit anti mouse (Sera) Eurogentec 
 Anti-CD23 Sheep Anti-human Binding site 
 Anti-CD23 Mouse Anti-human (mono) DAKO 
 Anti-CD23-FITC Mouse Anti-human Dianova 
 Anti-Integrins Rabbit/mouse anti-human SantaCruiz 
 Anti-Integrins-FITC   Mouse Anti-human   ImmunoTools, 
Serotec 
                                                                                                            
Western blot and FACS analysis secondary antibodies conjugated with horseradish 
peroxidase (HRP), Cy2 or Cy3 were used. 
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Antibody                                           Dilution                                        Source 
 
Goat anti mouse HRP                       1:25000                                        Dianova 
Goat anti rabbit HRP                        1:25000                                        Dianova 
Donkey anti sheep/goat HRP            1:25000                                       Binding site 
Donkey anti Goat F(ab)2                   1:150                                           Dianova 
Goat anti mouse IgG Cy2                 1:150                                           Dianova 
Goat anti mouse IgG Cy3                 1:150                                           Dianova 
 
4.8   Plasmids 
 
Vector                                              Description                                           Source 
 
pcDNA3                    Mammalian expression vector, Ampr, Neor,              Invitrogen  
                                  CMV promoter, BGH poly A, SV40 origion 
pCEP4                        Mammalian expression vector, Ampr, Neor,              Invitrogen  
                                   CMV promoter, BGH poly A, EBNA-1, EBV 
                                   origion 
                  
pAC5.1A                   Drosophila expression vector, Ampr, actin 5C (Ac5) Invitrogen 
                                   promoter, BGH poly A, pUC origin.  
 
4.9   Peptides 
 
Peptide                                           Sequence                                                  Source 
                                                                 
Cyclic hADAM8   H2N-AGEL (S-) CRPKK DM (S-) CDLEE-COOH        Eurogentec 
CD23 (149)           H2N-SHHGDQMAQKSQSTQI-COOH                          Eurogentec 
          (148)            H2N-SQVSKNLESHHGDQMAQKSQS-COOH            Eurogentec 
          (147)            H2N-LRAEQQRLKSQDLE-COOH                                Eurogentec 
 
4.10   Software 
Adobe photoshop 6.0                                                            Adobe Systems incorporated 
Cell Quest Pro                                                                        Becton Dickinson 
Corel Draw 9                                                                         Corel Corporation LTD 
Mac OS 8.6                                                                           Apple Computer, Inc. 
Office XP                                                                               Microsoft Corporation 
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Windows XP                                                                          Microsoft Corporation 
4.11   Methods in Molecular Biology 
 
Unless otherwise stated standard protocols were used as described elsewhere (Sambrook 
2001). 
 
4.11.1          Cloning of soluble human CD23-His6  
 
Two different constructs (W45 and L102) of soluble human CD23-His6 including at 
their 5' end the Bip signal sequence EcoRI and at the 3' primer including XhoI 
restriction site. Fragments were digested by EcoRI and XhoI and then inserted into 
pAC5.1 vector. The constructs were then transfected into DES cells. Transfection was 
carried out in 6 well plates (1x106 cells/ml), two solutions were prepared in sterile vials, 
solution A contained 19µg of DNA, 1µg pCoHygro, 36µl 2M CaCl2 and Millipore 
water making the total volume 300µl. Drop wise solution A was added to solution B 
[(2x Hepes Bufferd Saline) (HBS)] and incubated at room temperature for 30 minutes. 
The mixture was added drop wise to the cells and incubated over night at 22˚C. In the 
following day cells washed 2 times with DES complete medium and 4ml of fresh 
medium was added and cells incubated for 2 days. After 2 days the medium was 
exchanged with fresh medium containing hygromycine (400µg/ml).     
 
4.11.2        Cloning of soluble mouse ADAM8-Fc 
 
A full length cDNA of mouse ADAM8 was provided by Dr. J. W. Bartsch. The PCR 
product was fused with Fc part of human IgG1. Once the sequences were verified, it was 
then digested with EcoRI and XbaI and ligated into pBluescript KS/SK(+;-) and 
transformed into XL1 blue. Miniprep DNA was made and the product was verified by 
enzymatic restriction. The DNA was then inserted into pCEP4 and ligated over night at 
16˚C. Ligation was confirmed by digestion with BamHI and HindIII. Purified DNA was 
transfected into HEK-EBNA1-293 using Fugene transfection kit. Soluble ADAM was 
detected by western blot analysis. Furthermore, cellular subcloning was made and 
clones of higher yield were selected. 
    
4.11.3         Cloning of soluble human ADMA8-His6 
 
RNA was extracted from THP-1 cells, and used as template to synthesized cDNA. 
cDNA template was then amplified by PCR and the PCR product was cleaned using a 
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Roche kit. The product was digested using BamHI and NotI, ligated over night at 16˚C 
into pKS bluescript and transformed into XL1 blue. Colonies were grown over night at 
37˚C with continuous shaking and DNA was extracted using Macherey-Nagel 
extraction kit and digested with XhoI and sent for sequencing. Clones with correct 
sequences identified, in the same time 3' His-6 fragment was cloned and sequenced, and 
digested with BamHI/NotI, 5' digested with Hind III/NotI. Fragments were inserted into 
pCEP4 digested with HindIII/BamHI and ligated over night and then transformed into 
XL1 Blue. Miniprep was made and clones with proper insert size were transfected into 
COS-1, and surface expression was detected by FACS and western blot. 
 
4.11.4       Plasmid preparation in analytical scale 
 
Small amounts of plasmid DNA were prepared by the “boiling method” as describe 
(Del Sal et al.,1988). 3ml of E.coli culture were harvested and resuspended in 400µl 
STET-buffer containing Lysozyme (1mg/ml). After 10 minutes on ice the sample was 
heated to 95˚C for 45 seconds. After centrifugation at 13000rpm for 10 minutes, the 
pellet was removed and the supernatant mixed with 16µl 5% (w/v) CTAB. The sample 
again was centrifuged for 5 min at 13000rpm and the pellet dissolved in 150µl 1.2M 
NaCl. The DNA was then precipitated with ethanol using a standard protocol 
(Maniantis 2002). The DNA pellet dissolved in 20µl TE buffer. 
High quality DNA for sequencing was prepared using Miniprep-Kit (Macherey-Nagel). 
 
 
4.11.5    Plasmid large scale preparation (Maxiprep) 
 
High quality DNA was prepared using AX500 Maxi Kits (Macherey-Nagel). This DNA 
was used for transfection. 
 
4.11.6    Enzymatic manipulation of DNA 
 
4.11.6.1 Digestion of DNA with restriction enzymes 
 
Restriction endonuclease cleavage was accomplished by incubation the DNA fragment 
with the enzyme (s) under recommended reaction conditions. The amount of the 
enzyme and DNA, the type of buffer, temperature and the duration of the reaction was 
carried out according to the manufacturer's recommendations. 
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4.11.6.2  DNA insert ligation into the vector 
 
T4 DNA ligase was used to catalyze the formation of phosphodiester bond between the 
5´-phosphates of the insert DNA and the 3´-ends of vector DNA. In a total volume of 
20µl the digested, dephosphorylated, and purified vector DNA (10ng) and insert DNA 
in a 3-5 molar excess were incubated with 4 U T4 DNA ligase in ligase buffer at RT for 
2 hours. 5µl of the resulting ligation reaction mixture was used for bacterial 
transformation.  
 
4.11.7   Agarose gel electrophoresis 
 
0.8-1.2% horizontal agarose gels were used. Gels were prepared by boiling agarose in 
1x TAE buffer and ethidium bromide (0.5µg/ml) was added after slight cooling. The 
voltage was set at 5V/cm electrode distance. Under conditions in which LMP-agarose 
was used, bands of interest were excised. The gel slice was then melted at 70˚C with 
appropriate amount of water in order to reduce the agarose content.  
 
4.11.8   Insertion of plasmid DNA into E.coli  
 
4.11.8.1 Preparation of competent XL1 Blue 
 
Only one colony of XL1Blue from a LBT/Tet-plate (7µg/ml) is inoculated into 5ml 
LBT/Tet (7µg/ml) and grown over night at 37˚C with continues shaking. 1ml of this 
culture added to 150ml LB/Tet (7µg/ml) and grown under same condition until OD600 
in the range 0.45-0.55. Culture kept on ice for 10 minutes, then harvested by 
centrifuging for 15 minutes at 4˚C at 4000rpm. The pellet is then resuspended in 10ml 
Tfb1 and incubated on ice for 5 minutes. The suspension is harvested as previously 
stated. The pellet is then resuspended in 2ml Tfb2 and aliquots (50µl) are shock frozen 
in liquid nitrogen and immediately stored at -70˚C.  
 
4.11.9   Methods in cell culture 
 
General cell culture techniques 
 
4.11.9.1        Culture condition 
 
All cell lines were grown at 37˚C, relative humidity of 90% and CO2 content of 5%. 
Cells were generally cultured without antibiotics. 50µg/ml gentamycine is added after 
transfection for one week. 
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4.11.9.2        Culture of adherent cell lines 
 
Adherent cells lines COS-1, HEK293-EBNA1, CHO were cultured in DMEM (10% 
FCS, 2mM Glutamine, 30ml Goodies F). In order to keep selective pressure, HEK293-
EBNA cells were cultured in the presence of 250µg/ml G418 and 400µg/ml 
hygromycine. CHO cells transfected with integrin subunits were cultured in presence of 
100µg/ml G418. CHO cells expressing CD23 were cultured in presence of tetracycline 
(1µg/ml) and G418. Confluent cells were washed with cold PBS and then splitted by 
using 1.0ml Trypsin/EDTA and incubated for 5 minutes at 37˚C. The detached cells 
were resuspended in DMEM 10% FCS and then seeded again. 
 
4.11.9.3        Culture of suspension cells 
 
THP-1 and U937 were cultured in RPMI 10% FCS at 0.5-3x106 cells/ml. When cells 
reach high density, they were splitted in a ratio of 1:3. Cell density was determined 
using Neubauer counting chamber. 
 
4.11.9.4        Thawing and freezing of cells 
 
Cells were centrifuged at 1000rpm for 5 minutes at 4˚C and resuspended at a density of 
1x107 cells/ml in complete cold freezing medium containing 10% (v/v) DMSO, HEK, 
CHO and U937 cells were frozen in cold medium (45% preconditioned medium, 45% 
fresh medium and 10% (v/v) DMSO). 1ml aliquots were frozen over night at -70˚C in 
polystyrene box and then stored in liquid nitrogen. Cells were thawed by placing the 
vial in 37˚C water bath. Cells then were washed in 10ml of culture medium and 
resuspended in fresh culture medium.  
 
4.11.9.5         Transfection of cultured cell lines 
 
COS-1 and HEK 293-EBNA1 cells were transfected using Fugene6 transfection reagent 
and conducted according to the manufacturer's recommendations. 24 hours before 
transfection, cells were trypsinized and grown to about 60-70% confluence on 6cm dish 
in 3ml DMEM. 3:1 (Fugene6: DNA) were added to DMEM serum free (SF) up to 
100µl, mixed well and incubated in RT for 30 minutes. The mixture was then added 
drop wise through out the dish. 24 hours later the medium replaced with fresh medium 
containing 50µg/ml gentamycine and further cultured for 48 hours. Stably transfected 
cells were selected with 400µg/ml hygromycine. The transfection efficiency monitored 
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by transfecting cells in parallel with GFP. Selection efficiency was controlled by 
culturing wild-type under same condition. 
 
4.11.10        Protein analytical methods 
 
4.11.10.1        CD23 Peptides cleavage assay 
 
Purified soluble mADAM8-Fc or hADAM8-His (2.4µg) were incubated with 20µM 
CD23 peptides of the stalk region in peptide assay buffer (total volume 20µl). Samples 
were incubated at 37˚C for 1-8 hours in presence or absence of EDTA. The reaction 
was stopped by shock freezing samples at -70˚C. Before loading peptide into the plate, 
tip was pre wetted for at least 5 cycles using wetting solution (acetonitrile:water). Tips 
then equilibrated for at least 5 cycles using equilibration solution (0.1% trifluoroacetic 
acid in water). Peptides then bound to ZipTip by aspirating and dispensing the sample 
for 10 cycles. Tips then washed for 5 cycles using washing solution (0.1% TFA in water 
and 5% methanol). 1μl of the peptide elutted in elution solution (50% Acetonitrile in 
0.1% TFA) and mixed with 1μl matrix (α-cyano-4-hydroxycinnamic acid in elution 
buffer). The matrix and the peptide were left to co-crystalised in a MALDI spot. The 
cleavage products were detected by matrix-assisted laser-desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry (Applied Bioscience instrument). 
 
4.11.10.2         Preparation of cell lysates and supernatants 
 
Cells lysates were prepared by treating cells with 1mM EDTA for about 5 minutes at 
37˚C and then washed with PBS. Cell pellets were resuspended in lysis buffer (100µl). 
The pellets were sheared by passing through needles (17 gauges) and then incubated on 
ice for about 10 minutes. Cells lysates were cleared by centrifuging for 20 minutes at 
13000rpm at 4˚C. Supernatants were prepared by filtering it after centrifuging at 
1500rpm. The cleared supernatants were 10 fold concentrated by ultra filtration using 
Amicon columns (Millipore). 
 
4.11.10.3        SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The analytical separation of proteins is accomplished by discontinuous SDS-PAGE as 
described by Paulson and Laemmli, 1977. Resolving and stacking gels were 
sequentially prepared as shown in table 1. Samples were prepared by boiling in 2x 
Laemmli buffer for 5 minutes. Electrophoresis was conducted at 10mA for stacking gel 
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and 20mA for the resolving gel. LMW (low molecular weight) or prestained markers 
were used as standard. 
 
Table 1. Composition of SDS-Polyacryamide gels 
 
                                                     Resolving gel                                      Stacking gel 
 
Composition/Percentage             7.5       10       12.5        15        17.5          3           5 
  
H2O (ml)                                     2.64     2.04      1.39      0.76      0125       0.945     0.775 
 
1M Tris/HCl pH 8.8 (ml)           2.81      2.81      2.81      2.81      2.81         -             -  
 
30%AA/0.8%BA (ml)               1.88     2.45        3.13      3.75      4.38       0.255     0.425 
  
0.25M Tris/HCl pH 6.8 (ml)        -          -             -            -           -           1.25       1.25 
 
5% (w/v) SDS (µl)                     150      150          150     150       150         50          50 
 
TEMED (µl)                               4          4              4         4            4            3           3 
 
10% (w/v) APS (µl)                   60        60            60       60         60           35         35 
 
 
4.11.11    Western-Blot analysis 
 
For immunoblot analysis proteins were transferred into nitrocellulose membranes for 2 
hours at 300mA using wet blotting chamber (BioRad). Gels and membranes were 
preincubated in transfer buffer for 30 minutes. Following transfer membranes were 
stained with Ponceau solution in order to determined the standard, if prestained marker 
was used the membrane was not stained. The membrane was destained using water. 
After electroblotting membrane were blocked and treated in accordance with the protein 
investigated.  
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Table 2. Primary and secondary antibodies used to probe proteins by western analysis. 
 
 Probed protein                        Primary antibody                                Secondary antibody 
 
Human ADMA8-6xHis     Rabbit anti mouse (Sera)                Goat anti mouse HRP 
Human ADMA8-6xHis     Rabbit anti mouse (IgG)                 Goat anti mouse HRP   
Human ADMA8-6xHis     Goat anti human (Poly)                  Donkey anti-goat HRP    
Mouse ADAM8-FC          Goat anti human IgG1-Fc HPR                          -       
Mouse ADAM8-Fc           Goat anti mouse (Poly)                   Donkey anti-goat HRP                      
Mouse ADAM8-Fc           Rabbit anti mouse (Sera)                Goat anti mouse HRP 
Mouse ADAM8-Fc           Rabbit anti mouse (IgG)                 Goat anti mouse HRP             
Anti-CD23                         Sheep anti-human                           Donkey anti sheep/goat  
                                                                                                   HRP  
          
4.11.12     Cleavage of bovine myelin basic protein (bMBP) 
 
Activity of ADAM8 was assessed by using bovine myelin basic protein (bMBP) 
purchased from Upstate. 50µg of MBP incubated with 2.4µg of ADAM8 at 37˚C for 
time ranging from 0-2 hours. Under same condition, EDTA was used as 
metalloprotease inhibitor, as a negative control MBP was incubated in buffer only. 
Samples were reduced by 2xLaemli, 20µl were loaded into 17.5% SDS-PAGE gel, 
electrophoresis and then stained with Coomassie Brillinat blue. 
 
4.11.13     Silver staining 
 
After electrophoresis, gels were washed few times with Millipore water, then fixed with 
silver fixture for at least 15 minutes. Gels then stained with Farmer's reducing solution 
for 2 minutes, after that gels washed thoroughly until no background remains. Gels 
incubated for 15 minutes with 0.1% silver nitrate, washed with water for 30 seconds 
and then with 2.5% Na2CO3 for 30 seconds. Gels were developed with 50ml 2.5% 
Na2CO3 containing 80µl formaldehyde. Once the bands detected the reaction stopped 
with 10% acetic acid. Gels were dried using a gel dryer device. 
  
4.11.14     Large scale purification of soluble CD23 His6 tag 
 
Cells were grown in Schneider's Drosophila medium at 22˚C until they reach 2x106/ml. 
Cells then centrifuged and resuspended in fresh serum free medium. Cells were kept 
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under the same condition for 3 days. The supernatants collected and centrifuged at 4˚C 
for 3 minutes at 1000rpm, then filtered through 0.22µM. Supernatants were 
concentrated 10 fold using a Millipore concentrator, meanwhile buffer exchange was 
performed using same device and carried out on ice. This process was repeated twice 
using 4 atms. Concentrated supernatant was added to Ni-NTA agarose and kept mixing 
at 4˚C for one hour. After binding, agarose was washed 3 times with buffer (50mM 
NaH2PO4, 300mM NaCl) and then eluted by adding 250mM Imidazol to the similar 
buffer.  
 
4.11.15   Large scale purification of metalloproteases 
 
Cells were grown in DMEM complete medium at 37˚C, 5% CO2. Once cells reach 70-
80% confluency, cells were washed with cold PBS and serum free Pro293a medium 
was added. Cells were incubated for 48 hours and the supernatant was harvested and 
centrifuged at 1000rpm for 5 minutes at 4˚C. Supernatants were filtered sterile using 
0.22µM filters. Supernatants were incubated with protein A (Fc-tagged protein) or Ni-
NTA agarose (6xHis-tagged protein). Supernatants were left over night with continuing 
mixing at 4˚C. Agarose was collected and washed with cold PBS until OD280 is below 
0.05. Fc-tagged proteins were eluted by passing 3.2M glycine buffer (pH3.2) buffer. 
Proteins were neutralized immediately using 2M Tris-HCl buffer (pH8.8) and fractions 
containing the eluted proteins were determined by spectrophotometer. In 6xHis tagged 
metalloprotease, after binding, agarose was washed 3 times with buffer (50mM 
NaH2PO4, 300mM NaCl) and then eluted by adding 250mM Imidazol to the similar 
buffer. 
 
4.11.16    Binding of soluble human ADAM8-His6 to integrins 
 
CHO cells transfected with integrin subunits were grown in DMEM containing 
100µg/ml G418. Cells were grown for two days. On the day of the experiment, 
confluent 10cm plates were used for each type of cells line. Cells were washed with 
cold PBS and then treated with 1mM EDTA and incubated at 37˚C for 5 minutes. Cells 
then washed twice with cold PBS and then blocked in Tyrode's buffer for one hour at 
4˚C with continuous mixing. Cells were washed twice using cold PBS and then 
resuspended in 300µl Puckes buffer and 20µg of soluble human ADAM-His6 added. 
After one hour incubation with continuous mixing at 4˚C, the cells were washed twice 
using cold PBS and resuspended in 300µl cold PBS. 30µl (25µg/ml) of mouse anti 
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human ADAM8 monoclonal antibody was added and cells incubated for one hour at 
4˚C with continuous mixing. Cells then washed twice and resuspended in 300µl cold 
PBS, 1.5µl of goat anti mouse Cy3 was added and cells were further incubated for one 
hour in the dark at 4˚C with continuous mixing. Cells were then washed twice using 
cold PBS. Binding was detected using a FACS flow cytometry.  
 
4.11.17       Inhibition of binding of soluble human ADAM8-His6 to integrins 
 
CHO cells transfected with integrin subunits were maintained and treated in same way 
as for binding (section 3.11.16). Before adding hADAM8-His6, a cyclic peptide 
containing the amino acid sequences of the disintegrin loop of hADAM8 (H2N-AGEL 
(S-) CRPKK DM (S-) CDLEE-COOH) was added 100-500µM. Both peptide and cells 
were incubated for one hour at 4˚C with continuous mixing, and then soluble 
hADAM8-His6 was added and incubated for additional one hour. Afterwards, cells were 
washed and treated in the same way as for binding. Inhibition was detected using FACS 
flow cytometry.   
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5. Results 
 
5.1 Expression of mouse ADAM8-Fc 
 
In order to establish stable expressing construct of mouse ADMA8-Fc, the construct 
encoding the complete extracellular domains (pro, metalloprotease, disintegrin and 
cysteine rich domains) was transfected into HEK-EBNA 293 using Fugene 
transfection kit.  48 hours later part of the cells was made serum free and incubated 
for additional 48 hours at 37˚C. The supernatant was collected, centrifuged and 
filtered to remove any debris. Secretion of soluble ADAM8 was examined by silver 
stain and Western blot. Various fragments were detected, 98kDa (mature form with 
Fc), 70kDa (mature form) and a 33kDa (The Fc fragment). Once the expected mature 
metalloprotease was detected, single cell clones were isolated by limiting dilution. 
Clonal expansion was made and the soluble mouseADAM8-Fc was verified using 
goat anti mouse IgG Fc labelled peroxidase antibody and rabbit anti mADAM8 
serum. 
  
                                    
Figure. 5.1 Detection of ADAM8. A: coomassie stains of mADAM8-Fc, BSA was used in order to 
determine its concentration. LMW marker (lane 1), BSA (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0µg/μl) 
lanes (2-9) respectively, purified mADAM8-Fc, 1.2μg/μl (lane 10). B: Western blot of mADAM-Fc 
probed with goat anti-mouse IgG Fc Peroxidase labelled antibody. Proteins were reduced and separated 
on a 10% SDS-PAGE The 98kDa protein is the proform, about 70kDa is the processed form and 
33kDa is Fc fragment of mADAM8-Fc  
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5. 2 Characterisation of rabbit anti mouse ADAM8-Fc sera 
 
The entire soluble form of ADAM8-Fc was used to generate polyclonal rabbit 
antiserum. Both serum and affinity purified antibodies were used to detect mouse 
ADAM-Fc. 
 
 
                                                  
 
 
 
Figure. 5.2.1 Rabbit anti mouse ADAM8-Fc polyclonal antibodies. A: diluted Rabbit anti-  
mADAM8-Fc serum (1:10,000) used to detect mADAM8-Fc (50, 100, 200,300 and 500ng/lane) lanes 
1-5 respectively. B: affinity purified rabbit anti-mADAM8-Fc (0.2ug/ml) used to detect mADAM8-Fc 
(50, 100, 200,300 and 500ng/lane) lanes 1-5 respectively. Bands sizes are correlates with figure (4. 1). 
 
 
In addition, the antisera were examined to find out if they are suitable for flow 
cytometry and able to bind to ADAM8 expressed on cell the surface. P388D1 (mouse 
macrophage cell line) cells were used to detect ADMA8 expression. Cells were 
maintained under normal condition. On the day of the experiment cells were adjusted 
to 1.0x106, washed with cold PBS and blocked using 1% BSA. After washing, serum 
or antibodies (bleeding of Feb. 2005) were added and cells further incubated. Cells 
washed and secondary goat anti rabbit antibody (Cy2) was added. Referring to figure 
3.2.2, it appeared that the antisera is applicable for flow cytometry, significant shift 
when immune sera used (E, Geo mean = 138) and affinity purified IgG antibodies (F, 
Geo mean = 111.4). Very low detection was observed when preimmune serum was 
used (C, Geo mean = 17) and when affinity purified IgG antibodies from preimmune 
serum (D Geo mean = 20.8). The horizontal axis (X) of each histogram reflects the 
relative fluorescent intensity and shifts to the right with increasing protein expression 
levels. The vertical axis (Y) reflects relative cell number expressing the investigated 
protein.  
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          Goat anti Mouse (Poly)           Goat anti mouse (Mono) 
                               
 
Figure 5.2.2 Test of rabbit anti mADAM8-Fc (serum and affinity purified antibody) using flow 
cytometry. Autoflouresence generated by cellular organelles (A), cells incubated with goat anti rabbit 
secondary antibodies (Cy2) (B), cells incubated with preimmune sera (C), incubation with affinity 
purified preimmune sera antibodies (D), incubation with immune sera (E) and with affinity purified 
antibodies (F). In addition, as a control, commercial anti-ADAM8 antibodies were used, polyclonal 
antibody (G) and monoclonal antibody (H).  
 
In all histograms (X) axis: relative fluorescent intensity and (Y) axis: relative cell 
number 
       
5.3 Verification of soluble mADAM8-Fc activity 
 
The activity of the metalloproteases needs to be verified. In order to know whether the 
purified soluble mouse ADAM8-Fc is active or not, bovine myelin basic protein 
(bMBP) was first used as a substrate. Such activity was controlled by incubating the 
substrate without metalloprotease or in presence of the light metal chelator EDTA. 
The active mADAM8-Fc cleaved the substrate within 30 minutes, but complete 
cleavage was achieved only after 2 hours. After 2 hours the entire substrate was 
degraded and two main products were generated. The cleavage products were 
GM= 3.7 GM= 5.6 GM= 17
GM= 20.8 GM= 138 GM= 111.4 
GM= 59.4 GM= 40.9
A B C 
D E F 
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approximately 17kDa, and 18kDa. Neither in the absence of mADMA8-Fc nor in the 
presence of EDTA could any cleavage of the substrate be observed.  
 
 
 
   
                         
 
 
 
 
 
 
 
 
 
 
5.4 Stability of soluble mouse ADAM8-Fc 
  
It had been suggested that by keeping mADAM8 at 4ºC for about 4 weeks would 
generate active protease by autocatalytic process. Such activity has been described by 
Schlomann et al (2002). Here active soluble mADAM8-Fc was investigated by 
incubating it up to three months. The immune blot of this protease was probed using 
rabbit polyclonal anti ADAM8-Fc sera. No difference was observed through out all 
incubation period. In all times of incubation, only the original fragments could be 
detected. A small band observed at, 2nd, 3rd and 4th weeks. Since no difference 
between 0 and 12 weeks observed, this is most likely to be an artefact. 
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Figure. 5.3 Cleavage of bovine myelin basic protein (bMBP) by mADAM8-Fc. A: lanes 2, 3, 4 and 5 are 
bMBP (50μg) incubated with buffer only at 0, 0.5, 1.0 and 2.0 hours respectively. Lanes 6, 7, 8 and 9 are 
bMBP (50μg) incubated with mADAM8-Fc (2.4μg) but in presence of EDTA (20mM) at 0, 0.5, 1.0 and 2.0 
hours respectively. No cleavage product was detected in both cases. B: bMBP treated in similar way but 
with ADAM8-Fc and without EDTA, two cleavage products were generated (17 and 18kDa). Samples were 
analysed in 17.5% SDS-PAGE under reducing conditions 
A B 
             0      1       2    3     4     12   
            Time of incubation (wks)  
 
Figure. 5.4 Stability of mADAM8-Fc. Purified active mouse ADAM8-Fc was 
incubated at 4˚C for various intervals in order to find out if other fragments 
would be generated.  Bands after 0 and 12 weeks were identical. 
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5.5 Cleavage of CD23 peptides  
 
Active mADAM8-Fc was also used to find out if it is able to cleave various peptides of 
the stalk region of human CD23. The designed peptides are assumed to contain the 
putative cleavage sites: 
a) H-LRAEQQRLKSQDLE-OH (containing the putative 33kDa cleavage site) 
b) H-S73HHGDQMAQKSQSTQI88-OH (containing the putative 37kDa cleavage site) 
c) H-S65QVSKNLESHHGDQMAQKSQS85-OH (containing the putative 37kDa 
    Cleavage site) 
Peptides b and c contain the putative 37kDa cleavage site but they differ in length. The 
generated products were analysed by MALDI-TOF and the cleavage sites were 
identified by using POMWIN programme (http://www.crc.dk/spocc/downl_1003.htm). 
Cleavage of the peptides was carried out at various intervals. In addition, samples were 
incubated with the metal chelator EDTA or with buffer only i.e without 
metalloprotease. This is to insure that the cleavage products were due to the 
metalloprotease (ADAM8). Before starting shooting the digested samples, the 
instrument has to be calibrated with various standards. Fours different standards were 
used (Angiotensin I, Bradykinin, Insulin, Insulin Chain β). The mass of particles 
expressed horizontally and the intensity expressed vertically. 
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Figure. 5.5 Spetcrum of different standards were used to calibrate the 
instrument prior the measurement. Bradykinin (573.3149 Da), Angiotensin I 
(1296.5 Da), Insulin chain β (3495.89 Da), Insulin (5730.608 Da)  
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5.5.1 Cleavage of peptide # (147) H-LRAEQQRLKSQDLE-OH containing the 
putative 33kDa cleavage site. 20µM of CD23 peptides were incubated with 2.4μg 
mADAM8-Fc in peptide assay buffer (total volume 20µl). Samples were incubated at 
37˚C for 1-8 hours in presence or absence of EDTA (20mM). The cleavage products 
were detected by MALDI-TOF mass spectrometry. Products were identified by using 
POMWIN software.   
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Fig. 5.5.1a Peptide # 147+buffer, 0hrs. 
Fig. 5.5.1b Peptide # 147+ADAM8, 0hrs. 
Fig. 5.5.1c Peptide # 147+ADMA8+EDTA, 0hrs. 
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Fig. 5.5.1d Peptide # 147+buffer, 4hrs. 
Fig. 5.5.1e Peptide # 147+ADMA8, 4hrs. 
Fig. 5.5.1f  Peptide # 147+ADMA8+EDTA, 4hrs.
Fig. 5.5.1g Peptide # 147+buffer, 8hrs. 
H-LRAEQ   QRLKSQDLE-OH 
Results 51
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
2447.2
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1116.3, 2447]
1116.43
616.15
1138.91
1154.59
1121.18
638.12
1160.96
1716.47
  
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
9.1E+3
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1714.9, 9062]
1715.12
1737.27
1753.35
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.5.1h Peptide # 147+ADAM8, 8hrs. 
Fig. 5.5.1i Peptide # 147+ADAM8+EDTA, 8hrs. 
H-LRAEQ   QRLKSQDLE-OH 
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5.5.2 Cleavage of peptide # (148) H-S65QVSKNLESHHGDQMAQKSQS85-OH                               
containing the putative 37kDa cleavage site.  
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Fig. 5.5.2a Peptide # 148+buffer, 0hrs. 
Fig. 5.5.2b Peptide # 148+ADMA8, 0hrs. 
Fig. 5.5.2c Peptide # 148+ADMA8, 4hrs. 
H-S65QVSKNLESHHGDQMA QK SQS85-OH 
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Fig. 5.5.2d Peptide #148+ADMA8+EDA, 4hrs. 
Fig. 5.5.2e Peptide # 148+buffer, 8hrs. 
Fig. 5.5.2f Peptide # 148+ADAM8, 8hrs. 
Fig. 5.5.2g Peptide # 148 +ADAM8+EDTA, 8hrs. 
H-S65QVSKNLESHHGDQMA QK SQS85-OH 
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5.5.3 Cleavage of peptide # (149) H-S73HHGDQMAQKSQSTQI88-OH                                   
containing the putative 37kDa cleavage site  
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Fig. 5.5.3a Peptide # 149+buffer, 0hrs. 
Fig. 5.5.3b Peptide # 149+ADAM8, 0hrs. 
Fig. 5.5.3c Peptide # 149+ADAM8+EDTA, 0hrs. 
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Fig. 5.5.3d Peptide # 149+buffer, 4hrs. 
Fig. 5.5.3e Peptide # 149+ADAM8, 4hrs. 
Fig. 5.5.3f Peptide # 149+ADAM8+EDTA, 4hrs. 
Fig. 5.5.3g Peptide # 149+buffer, 8hrs. 
H-S73HHGDQMA  QKSQ STQI88-OH
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In summery mADAM8-Fc cleaved both peptides containing the 37kDa cleavage site in 
identical position of the hypothesized consensus sequences constructed from the 
cleavage of large fragments (A-Q) (207). It also cleaved peptide containing the 33kDa 
cleavage site very close to the cleavage position constructed from the cleavage of the 
large fragment (R-L) (207).    
 
A) H-LRAEQQRLKSQDLE-OH (33kDa), mADAM8-Fc cleaves between Q-Q aa. 
B) H-S65QVSKNLESHHGDQMAQKSQS85-OH (37kDa) 
C) H-S73HHGDQMAQKSQSTQI88-OH (37kDa)  
mADAM8-Fc also cleaved peptides containing the 37kDa cleavage site at A-Q 
 
 
 
 
 
 
 
 
 
Fig. 5.5.3h Peptide # 149+ADAM8, 
Fig. 5.5.3i Peptide # 149+ADAM8+EDTA, 
8h
H-S73HHGDQMA  QKSQ STQI88-OH 
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5.6 Cleavage of sCD23 by mADAM8-Fc  
 
Three soluble forms of CD23 were used in order to find out if mADAM8-Fc is able to 
cleave any one of them and what type of product would it generate. The longest form 
(W45) which is 39kDa represents the complete ectodomain of CD23 and this 
fragment contains all putative cleavage sites. The shortest form (M150) which is a 
25kDa predicted not to contain any putative cleavage site. It appears that mADAM8-
Fc cleaves the sCD23 ectodomain (sCD23-W45) generating 37, 27 and 25kD. Zinc 
chelator 1, 10-phenanothroline was used as metalloprotease inhibitor.   
 
 
  
 
 
 
 
 
5.7 Co-transfection of CD23 mutants and mADAM8 in COS-1 cells 
 
It had been suggested that basic residues such as lysine or arginine are preferred at the 
cleavage site of large fragment of CD23. To find out if changing of various amino 
acids in sites them more susceptible to mADAM8-Fc, various mutants were made as 
shown in figure 5.7. The mutants were co-transfected with mADAM8-Fc into COS-1 
cells. The generated fragments were analysed by Western blot.  
 
 
 
 
 
 
 
 
    1,10 phenanothroline: +
Figure. 5.6 Immunoblot of sCD23 from transfected DES cells.  Supernatants were collected from 
transfected DES cells after 3 days. Supernatants were filtered and concentrated to 20 folds. In addition to 
mADMA8-Fc, proteins were incubated with metalloprotease inhibitor (1,10 phenanothroline). Proteins were 
analysed using 12.5% SDS-PAGE under reduced condition  
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The above figure shows that mutated CD23 (K82E, 37kDa) and (Q100A, 33kDa) 
appears to be more susceptible to mADAM8-Fc activity comparing to the wild type 
sCD23. As shown in figure B, the main fragments were better cleaved i.e. more 
susceptible to mADAM8-Fc and more 25kDa band was generated.  
 
5.8 Human ADAM8-His6 (hADAM8-His6) 
 
Soluble human ADAM8 was fused with a C-terminal 6 Histidine tag. Initially it was 
transfected in COS-1 cells and its expression was verified by Western blot. 
Furthermore, HEK-EBNA 293 cells were used to establish stable expression of the 
soluble form; this was achieved by using the Fugene transfection reagent. Serum free 
supernatant was collected after 48 hours and hADAM8-His6 was detected using anti 
His6 antibody. The soluble form appeared at 65kDa which is identical to the predicted 
size of mature form. In either case small aliquot from previously purified hADAM8-
His6 was added as control.   
 
                                 
 
                                                         
  hCD23b K82E Q100A                                                   hCD23b   K82E    Q100A        
Figure. 5.8.1 A: Silver stain of purified soluble hADAM8-His6, the 65kDa (1), another aliquot 
of hADAM-His6 used as control (2). B: Western blot of purified hADAM8-His6 probed with 
anti His6 antibody (1) and old hADAM8-His6 used as control (2). The sizes were in accordance 
with the predicted size i.e. 65kDa. 
Figure. 5.7 Immunoblot of co-transfection of sCD23 mutants and mADAM8. A: the mutants were 
transfected into COS-1 cells without ADAM8.  B: Co-transfection of CD23 mutants with mADAM8 
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In addition the Coomassie stain was used to roughly quantifying the product. As 
shown below, figure 3.7.1. Western blot and silver stain showed identical size 
(65kDa) of mature soluble hADAM8-His6. 
 
 
        
 
    
                                                                                                             
     
 
 
5.9 Cleavage of bMBP by soluble human ADAM8-His6 activity 
 
Soluble hADAM8-His6 activity was tested in similar way to mADAM8-Fc. Bovine 
myelin basic protein (bMBP) was used as substrate and the activity judged by 
analysing the protein cleavage pattern. As with mADAM8-Fc, active hADAM8-His6 
cleaved the substrate within 30 minutes. After 2 hours the entire substrate was 
degraded and two main products were generated. The cleavage products were 
approximately 16 and 18kDa. Comparing this with mADAM8-Fc, one of the cleavage 
products (16kDa) different from mADAM8-Fc (17kDa).  
 
 
 
 
 
 
 
 
 
Figure. 5.8.2 Coomassie stain of purified hADAM8-His6. It was quantified using BSA as a standard 
in order to determine its concentration. LMW marker (lane 1), BSA (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 
4.0µg/μl) lanes (2-9) respectively, purified hADAM8-His6, 1.2μg/μl (lane 10). Proteins were analysed 
on 10% SDS-PAGE under reducing conditions. The 65kDa is the mature soluble form of hADAM-His6.
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Blot (B) was made in order to rule out any degradation of the protease that might lead 
to false results. It appears that ADAM8 is stable as no significant degradation could d.   
 
5.10 Autocatalytic activity and stability of soluble human ADAM8-His6 
 
As with mADAM8-Fc, similar test was carried out to verify the stability and 
autocatalytic activity. Soluble active hADMA8-His6 was incubated at 4˚C for 4 
weeks. The immunoblot was probed with rabbit anti-mADAM8-Fc.serum No 
autocatalytic activity was observed as with mADAM8-Fc and mature hADAM8-His6 
seems to be stable. 
                                        
 
 
 
 
 
 
 
 
 
Figure. 5.9 Cleavage of bovine myelin basic protein (bMBP) by hADAM8-His6. A: b Coomassie stain of bMBP 
incubated with hADAM8 at various time intervals. B, the hADAM8-His6 was incubated under same condition to rule 
out any degradation product. Lanes 2, 3, 4 and 5 are bMBP (50μg) incubated with hADAM8 (2.4μg) at 0, 0.5, 1.0 
and 2.0 hours. Two cleavage products were generated (16 and 18kDa). Samples were analysed in 17.5% SDS-PAGE 
under reduced condition. B: Coomassie stain of soluble hADAM8-His6 incubated at 37˚ C for 2 hrs, Lanes 1 and 2 
are from two different patches. This is to ensure that cleavage products of bMBP are not due degradation generated 
from hADAM8-His.  
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Figure. 5.10 The immune blot of hADAM8-His. Purified active hADAM8-Fc was 
incubated at 4˚C for various intervals in order to find out if other fragments would be 
generated. No significant additional bands were generated during time course of 0-4 
weeks. 
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5.11 Cleavage of CD23-His6 ectodomain by soluble human ADAM8-His6 
 
The CD23 ectodomain (sCD23 W45-His) containing a BIP signal sequence was 
stably transfected into DES cells. Cells were incubated with serum free medium for 
three days. Culture was filtered and the protein purified as mentioned in material and 
methods.  
                                                             
                                                      
                     
 
 
 
 
The purified protein was then cleaved by hADMA8-His6 and the cleavage products 
were analysed by Western blot. The immunoblot was probed with anti CD23 or with 
anti His6 antibodies. hADAM8-His6 cleaved sCD23 (W45-His) generating 37, 33 and  
25kDa as shown in figure 5.11.1(C). hADAM8-His6 generated the 33kDa fragment 
which is very important in allergic reaction. No cleavage was generated when Zinc 
chelator 1,10-phenanothroline (P) was added.  
Referring to figure 5.6, although mADAM8-Fc and hADAM8-His6 share some 
similar products (37 and 35kDa), only hADAM8-His6 was able to generated the 
33kDa fragment. 
 
                            
 
 
 
 
 
 
 
 
 
39 kDa 
Figure. 5.11.1 Western Blot of sCD23-His produced by DES cells. Purified by Ni-NTA sepharose. 
A: protein detected by anti CD23 antibody. B: probed with anti His6 antibody. C: cleavage of sCD23 
(W45-His) using hADAM8-His6. In addition metalloprotease inhibitor (1,10 phenanothroline) was 
used, lane marked with (P).   
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5.12 Cleavage of CD23 peptides by hADMA8-His6 
 
Active hADAM8-His6 was also used to find out if it can cleave various peptides of 
the stalk region of human CD23. The peptides were designed according to the N-
termini sequences of soluble forms of CD23 collected from RPMI8866 culture 
supernatants (Mayer et al 2002). These peptides contain putative cleavage sites of 
either 33 or 37kDa fragments. The generated products were analysed by MALDI-TOF 
and the cleavage sites were identified by using POMWIN software. The cleavages of 
peptides were carried out at various intervals; in addition samples with light metal 
chelator EDTA or without metalloprotease were used. This is to insure that the 
products were due to the used metalloprotease i.e. hADAM8-His6.  
 
5.12.1 Cleavage of peptide # (147) H-S73HHGDQMAQKSQSTQI88-OH 
Containing the putative 37kDa cleavage site 
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Fig. 5.12.1a Peptide # 147+buffer, 0hrs.
Fig. 5.12.1b Peptide # 147+ADAM8, 0hrs.
Results 63
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
9.0E+3
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1713.6, 9021]
1714.11
1736.15
1751.60
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
1.0E+4
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1713.6, 10184]
1713.94
1736.09
1752.25
1695.62
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
6220.8
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1115.7, 6221]
1115.70
615.71
1098.62
  
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
8401.8
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1714.7, 8402]
1714.89
1737.24
2008.62
 
 
Fig. 5.12.1c Peptide # 147+ADAM8+EDTA, 0hrs. 
Fig. 5.12.1d Peptide # 147+buffer, 4hrs.
Fig. 5.12.1e Peptide # 147+ADAM8, 4hrs.
Fig. 5.12.1f Peptide # 147+ADAM8+EDTA, 4hrs. 
H-LRAEQ   QRLKSQDLE-OH 
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Fig. 5.12.1g Peptide # 147+buffer, 8hrs. 
Fig. 5.12.1h Peptide # 147+ADAM8, 8hrs. 
Fig. 5.12.1i Peptide # 147+ADAM8+EDTA, 8hrs.
H-LRAEQ   QRLKSQDLE-OH 
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5.12.2 Cleavage of peptide # (148) H-S73HHGDQMAQKSQSTQI88-OH 
containing the putative 37kDa cleavage site 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
2944.1
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 2328.7, 2944]
2328.65
2366.76
2390.78
522.78
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
4258.3
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 2350.7, 4258]
2350.72
2329.30
2371.95
522.86 2461.82
2008.77550.24
2318.81665.76
2467.71951.08517.10 1851.57 2438.71
1315.50
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
3666.0
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 2328.4, 3666]
2328.37
2349.91
2366.10
2374.08
522.79
 
 
Fig. 5.12.2a Peptide # 148+buffer, 0hrs.
Fig. 5.12.2b Peptide # 148+ADAM8, 0hrs. 
Fig. 5.12.2c Peptide # 148+buffer, 4hrs. 
Results 66
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
2973.8
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1790.4, 2974]
1790.58
1806.83
1768.57
925.82 1828.50
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
3036.2
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 2328.1, 3036]
2328.25
2349.90
 
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
3778.4
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 1789.1, 3778]
1789.21
1805.45
925.16 1826.54
 
 
499.0 999.4 1499.8 2000.2 2500.6 3001.0
Mass (m/z)
0
2114.8
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1[BP = 2327.1, 2115]
2327.19
2348.12
2352.05
 
 
 
Fig. 5.12.2d Peptide # 148+ADAM8, 4hrs. 
Fig. 5.12.2e Peptide # 148+Buffer, 8hrs. 
Fig. 5.12.2f Peptide # 148+ADAM8, 8hrs. 
Fig. 5.12.2g Peptide # 148+ADAM8+EDTA, 8hrs. 
H-S65QVSKNLESHHGDQMA QK SQS85-OH 
H-S65QVSKNLESHHGDQMA QK SQS85-OH 
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5.12.3 Cleavage of peptide # (149) H-S73HHGDQMAQKSQSTQI88-OH 
containing the putative 37kDa cleavage site 
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Fig. 5.12.3a Peptide # 149+buffer, 0hrs.
Fig. 5.12.3b Peptide # 149+ADAM8, 0hrs. 
Fig. 5.12.3c Peptide #149+ADMA8+EDTA, 0hrs.
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Fig. 5.12.3d Peptide # 149+buffer, 4hrs. 
Fig. 5.12.3e Peptide # 149+ADMA8, 4hrs. 
Fig. 5.12.3f Peptide # 149+ADMA8+EDTA, 4hrs. 
Fig. 5.12.3g Peptide # 149+buffer, 8hrs. 
H-S73HHGDQMA  QKSQ STQI88-OH
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In summery as with mADAM8-Fc, hADAM8-His6 cleaved both peptides containing the 
37kDa cleavage site in identical position of the hypothesized consensus sequences 
constructed from the cleavage of large fragments (A-Q) (207). It also cleaved peptide 
containing the 33kDa cleavage site very close to the cleavage position constructed from 
the cleavage of the large fragment (R-L) (207).    
 
A) H-LRAEQQRLKSQDLE-OH (33kDa), mADAM8-Fc cleaves between Q-Q aa. 
B) H-S65QVSKNLESHHGDQMAQKSQS85-OH (37kDa) 
C) H-S73HHGDQMAQKSQSTQI88-OH (37kDa)  
hADAM8-His6 also cleaved peptides containing the 37kDa cleavage site at A-Q 
 
 
 
 
 
 
 
 
 
Fig. 5.12.3h Peptide # 149+ADAM8, 8hrs. 
Fig. 5.12.3i Peptide # 149+ADMA8+EDTA, 8hrs. 
H-S73HHGDQMA  QKSQ STQI88-OH
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5.13 Binding of human ADMA8-His6 to integrins expressed in transfected CHO  
        cells 
 
Due to the existence of a disintegrin domain in the ADAMs, it is anticipated that this 
domain is involved in binding to the integrin subunits. It has been shown that 
disintegrin domain of human ADAM15 binds to αvβ3 and α5β1 (57) 
  
5.13.1 Expression of various integrin subunits 
 
Integrin subunits are widely expressed, and expressed as αβ heterodimers. In this 
study CHO cells, provided by Dr Takada (Scripps research institute La Jolla, USA) 
were used. Integrins are endogenously expressed; therefore cells that express mainly 
β1 were identified. Briefly, clones were established by transfecting various cDNAs of 
various integrin subunits. Integrins expressed on cells surface as heterodimers as 
shown below (diagram 3.12). Heterodimeric expression was sorted using cells sorter 
and cell lines with various combinations established. In this experiment the following 
integrin subunits expressed by CHO cells were used: (α2β1, α3β1, α4β1, α6β1/β4, αLβ2, 
β3αV/αIIb) (51,221,222,223,224,225). The diagram below shows various combinations 
of integrin subunits. 
 
               
 
Diagram 5.13.1A. The various possible combinations of integrin subunits that can be expressed on 
cells surface (Chemicon). 
 
Before carrying out any binding experiment, the expression of integrin subunits was 
investigated. Wild type CHO cells did not show any expression of investigated 
integrin subunits and used as negative control. Figure 3.12. B shows summery of 
integrin subunits expression by the used CHO cells. The expression of various 
integrin subunits as GeoMean values. Alpha6 and Beta3 subunits were the most 
expressed. 
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              Wt                                        alpha2                                        Alpha3 
 
                 
                      Alpha4                                   Alpha6                                     Beta 3 
        
                    
               AlphaL Beta2 
 
 
 
 
 
5.13.2 Binding of integrins to hADMA8-His6 
 
After proving that respective subunits were well expressed on the various transfected 
CHO cell lines, the binding experiments were carried out. It has been found 20μg 
(hADMA8-His6)/300µl of cells suspension shows good sign of binding. Higher and 
lower amount of hADAM8-His6 also showed reasonable binding sign. Binding 
summery is shown in the figure below, α6 and αLβ2 showed strongest binding signs 
(GM=29).               
                                     
                    
GM= 21 GM= 307 
GM= 54.3 GM= 175.5 GM= 15.6 
GM=14/14.5  
Figure.  5.13.1 B. The expression of each integrin subunit used for binding with hADMA8-His6. The expression of 
subunits was expressed by GeoMean. The highly expressed subunits were found in α3 and α6 cells.  
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5.13.3 Inhibition of human ADAM8-His6 binding to various integrins 
      
After integrin subunits expression and soluble hADMA8-His6 bindings, inhibition of 
ADAM8 to integrin subunits was carried out. Since αLβ2 showed the strongest binding 
and was the most reproducible, it has been selected for inhibition experiment. A 
cyclic peptide containing the amino acid sequences of the disintegrin loop of 
hADAM8 was tested in order to find out if it blocks hADMA8-His6 binding to the 
integrin subunits. It was added at concentration of 100μM. The only inhibition was 
observed with αLβ2 and the degree of inhibition was weak (GeoMean from 46 to 37) 
as shown in figure 5.13.3.  
 
GM= 9.8 GM= 24.6 GM= 21.6 
GM= 12.7 GM= 28.9 GM= 19.4 
GM= 29 
Figure.  5.13.2 Binding of integrin subunits with soluble hADMA8-His6. α6 and αLβ2 showed strongest binding 
values (GeoMean=29).   
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                  Binding αLβ2                                 Overlay of binding with cyA8petide                      
      
               
      
                 
                          
 
Also higher concentration of the cyclic peptide was added (up to 500μM), and again 
very weak inhibition was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GM= 46 GM= 37.6
Figure. 5.13.3 Binding of αLβ2 subunits to hADMA8-His6 was weakly inhibited by the peptide used. At 
concentration of 100µM, binding of hADAM8 was dropped from GeoMean of 46 to 37. Dotted line is binding in 
presence of the peptide.  
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6. Discussion 
 
ADAMs (a disintegrin and metalloprotease domains) are a family of membrane-
anchored glycoproteins that have critical roles in variety of different processes 
including sperm-egg interactions, neurogenesis, muscle cell fusion, modulation of 
Notch receptor, ligand processing, and processing of the pro-inflammatory cytokine, 
TNFα (20,77,79,4,13,78). Only approximately half of the known ADAMs contain the 
catalytic site consensus sequence for metalloproteases (HEXXHXXGXXHD; 8,9 
189). ADAMs that contain a catalytic site have been shown to participate in the 
release of cytokines, growth factors and receptors from the cell membrane, a process 
that is referred to as protein ectodomain shedding (190, 191). The catalytic site is 
highly conserved. In addition, the disintegrin domain and cysteine-rich region of 
certain ADAMs have been implicated in cell-cell and cell-matrix interactions (192). 
Finally, ADAMs frequently contain potential signaling motifs such as SH3-ligand 
domains in their cytoplasmic domain. These are predicted to play a role in 
intercellular signaling and/or regulation of ADAM activity (81,10). 
To date, the biological roles of only a few catalytically active ADAMs have been 
elucidated. ADAM10 has a role in axonal guidance and Notch signalling 
(194,87,195). ADAM17/TACE (tumour necrosis factor-α [TNF-α] converting 
enzyme) was identified by its ability to cleave TNF-α (4,77). ADAM15 has a role in 
pathological neovascularisation in mice (196), whereas ADAM19 is essential for 
cardiovascular morphogenesis (197,198). Mutations in the ADAM33 gene have been 
linked to asthma and bronchial hyperresposivenss in humans (34).  
ADAM8 is a catalytically active ADAM that was initially identified in mouse 
macrophages and macrophages cell line by using differential display approach. 
ADAM8 is up-regulated in response to macrophage stimulators (199). In adult mice, 
ADAM8 expression has also been observed in the central nervous system, in neurons 
and oligodendrocytes (93). In addition, ADAM8 is expressed in human immune cells 
with exception of T cells (199). Promoter studies have identified LPS 
(lipopolysaccharide), interferon-γ, interleukin (IL)-6, and TNF-α response elements in 
the 5´ region of the ADAM8 gene (92,93). A biochemical characterization of 
recombinantly expressed soluble ADAM8 confirmed that it is possesses catalytic 
activity and demonstrated that ADAM8 is activated through autocatalytic removal of 
its inhibitory pro-domain (200,46). After identification of ADAM8 in macrophages, a 
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transgenic mouse overexpressing its soluble ectodomain was generated, these animals 
had attenuated leukocyte infiltration and down-regulated expression of L-selectin 
(97). Experiments in Wobbler mice, which have an accelerated course of 
neurodegeneration, showed an increase in ADAM8 expression in activated glial cells 
(astrocytes and activated microglia), suggesting that ADAM8 has a role in 
pathological neuron-glia interactions (93). Finally, ADAM8 reportedly can function 
as an adjuvant in the administration of vaccines against autoimmune diseases, 
although the mechanism underlying this effect remains to be established (201). The 
goal of this study is to further characterise soluble ADAM8 by expressing it in HEK-
293 EBNA cells and test it against various substrates (MBP, CD23). In addition 
evaluates its binding to various integrins.  
     
6.1 Expression of soluble ADAM8 
 
Soluble ADMA8 (human and mouse) were produced in HEK293-EBNA cells. The 
main reason for using these cells is due to that EBNA I expression enable the 
plasmids replicate episomally, which enhances the expression efficiency and makes 
the expression independent from any chromosomal integration site. In addition, using 
mammalian cells ensure appropriate glycosylation and the secreted protein will be 
well processed and the possibility of being in natural form is quite high. The mouse 
ADAM8 ectodomain was fused with human IgG1 Fc, to allow affinity purification by 
protein A. Because of its strong and specific binding to Fc fragment, protein A 
sepharose was used to purify the Fc tagged protein. The eluted protein was subjected 
for SDS-PAGE analysis, figure 3.1 (A) shows that various products including 
proform (98kDa), processed (70kDa) and the Fc fragment (33kDa). Such products 
sizes are in accordance with predicted sizes. This leads us to assume that soluble 
mADMA8-Fc is well processed and correctly folded as it to be mentioned later. The 
Fc fragment was confirmed by using goat anti human IgG-Fc peroxidase antibody 
(fig3.1 B).  
In addition to mADAM8, human extracellular ADAM8 was also expressed in HEK 
EBNA cells, but instead of fusing it with Fc, it was fused to His6 tag. Ni-NTA 
sepharose was used to affinity purification. SDS-PAGE analysis of purified protein 
(Figure 3.7 A & B) showed product of 66kDa, which correlates with the predicted 
size as deduced from the amino acid sequences. Furthermore, it was probed with anti 
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His6 antibody, and the outcome was identical as seen in figure 3.7B. Since it is 
expressed similar to mADAM8, we believe soluble hADAM8 is processed in the 
same way.  
Although both soluble human and mouse ADAM8 were subjected to SDS-PAGE 
analysis to identify the products and the purities were verified by silver stain, but 
amino acid sequencing would be more informative especially for mouse ADAM8. 
Each band should be sequenced and identify the amino acids of each band. This will 
identify the cleavage sites and will provide more information about processing and 
maturation of the corresponding protein.  
 
6.2 Rabbit anti-mouse ADAM8 serum 
 
Purified mADAM8-Fc was used to raise antibodies against mADAM8. The revealed 
rabbit anti mADAM8-Fc serum and purified IgG antibodies were tested against both 
human and mouse ADAM8. By considering mADAM8, we found that the serum is 
very sensitive. In Western blot it detects very low amounts of protein (50ng) at a 
1:10000 dilution (figure.3.2.1A). The detected fragments were identical with what 
was identified earlier by silver staining. Furthermore, IgG fractionated antibody was 
tested in the same way, and the outcome was very similar in terms of specificity but 
with decreased sensitivity (figure.3.2.1B). This is due to the loss or denaturation of 
the antibody during purification process.   
The previous results indicate that both serum and purified antibody are applicable for 
western blot analysis. We analysed if they are suitable to detect native ADMA8 i.e. by 
FACS analysis. Such tests were carried out using a mouse macrophage cell line 
(P388D1), since it is expected to express ADAM8 on the surface. As shown in figure 
3.2.2 (E & F), very low background signals are caused by the preimmune (serum and 
affinity purified) used. This is because of serum contains other proteins that would 
react with various proteins expressed on the cell surface.  
The cross reactivity is quite low and does not reduce the specificity and sensitivity of 
neither serum nor the purified antibody. This was very clear when they are applied to 
the same cells (figure 3.2.2 E & F). The detection significantly enhanced by many 
fold (7 folds in case of serum and 5.5 fold in case of affinity purified antibody). 
This indicates that both serum and affinity purified antibody are applicable for FACS 
analysis with a good level of specificity and sensitivity. Bearing in mind that both 
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serum and purified antibody had been used to detect endogenous expressed ADAM8, 
it is most likely that the sensitivity and specificity will be enhanced when it is used for 
transfected cells. As a control, polyclonal and monoclonal commercial antibodies 
were used. Our own antibody showed a higher sensitivity compared to them (figure 
3.2.2 G & H). The folding and conformation of some antibodies are affected during 
purification process, therefore, the sensitivity level deteriorate. This was not the case 
with our antibody. It seems that the conformation and folding of affinity purified 
antibody were preserved during the purification process.  
Since the homology between human and mouse ADAM8 ectodomain is about 75%, 
we decided to find out whether serum and affinity purified antibody are suitable to 
detect hADAM8. Although the level of sensitivity was lower in comparison to 
mADAM8, but the serum and affinity purified antibodies were cross reacted with 
hADAM8 and detect proteins with the appropriate sizes (data not shown). In case of 
the serum, 1:1000-1:2000 dilutions were suitable to detect 50ng of hADAM8. 
It is clear that rabbit anti mADAM8 serum and affinity purified antibody are suitable 
to detect mouse and human ADAM8, in addition they are applicable for FACS 
analysis. It would be wise to label this type of antibody with detection material such 
as Fluoresceine isothiocyanate (FITC) or Phycoerythrin (PE) and test it for both 
FACS and fluorescent microscopy. 
 
6.3 Activity of soluble mouse and human ADAM8               
 
6.3.1 Screening of potential substrate to determine ADAM8 activity 
Recombinantly expressed and purified soluble ADAM8 can cleave myelin basic 
protein (MBP), a peptide representing the membrane proximal region of IL-1 receptor 
type II (IL-RII), and CD23, a low affinity IgE receptor (200, 64,96). Therefore 
purified soluble ADAM8 (mouse and human), were tested in order to prove whether 
they are biologically active. First, MBP was used as substrate, and incubated with 
either human or mouse ADAM8. Both mouse and human ADAM8 preparations 
showed MBP cleavage (17 and 18kDa) already after 30 minutes incubation (figures 
3.2 and 3.8 respectively). It is difficult to compare the level of activities since 
mADAM8 is a dimer due to the Fc fragment whereas hADAM8 is monomer. 
Therefore the molarity was double in case of mouse through out the experiments. 
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Whether ADAM8 naturally exist as monomer or dimer is still unknown which has to 
be considered for in vitro experiments.   
Two prominent cleavage products were detected with an apparent molecular weight 
of 17 and 18kDa. Recently different products were reported with molecular weight of 
9 and 11kDa (200, 46). This difference is most likely due to the fact that we used the 
entire extracellular domains whereas in previous studies catalytic domains only were 
used. This indicates that it is important to use the complete extracellular portions of 
ADAMs for in vitro studies. Alternatively expressing the catalytic or metalloprotease 
domains in parallel to the entire extracellular domains and test them against MBP 
under same condition. This will provide a clear answer whether various domains leads 
to different cleavage products. This might resembles MMPs without the hemopexin-
like domains that led to the loss of substrate specificity.  
In addition to the previous mentioned suggestions, sequencing of cleaved products 
and determined the cleavage sites are very important. First, to determine whether 
MBP contains multiple cleavage sites that are recognised by ADMA8. Secondly, does 
various combinations of domains of ADAM8 leads to change in activity and 
recognition of substrates? Thirdly, is there any difference in sites recognition between 
human and mouse ADAM8? 
In our study we verified whether ADAM8 is active or not, ideally their activity level 
needs to be determined. This could be achieved by identifying the cleavage sites and 
this information would help to synthesize modified peptides. Quenched fluorescent 
peptide containing the cleavage sites will allow to determine the exact specific 
activity of ADAM8.   
This type of peptide can also be used as substrate to conduct kinetic analysis of 
ADAM8. Figures 3.2 and 3.8, indicated that MBP were degraded after 30 minutes, 
therefore kinetic analysis of ADAM8 is very important. This can be achieved by 
carrying out experiments at shorter time or reducing ADAM8 concentration which 
added to the substrate. This will also provide information whether if there are any 
intermediate products.               
Although bBMP seems to be as good substrate for both mouse and human ADAM8, 
testing hADAM8 against human MBP is very meaningful. Cleavage of hMBP by 
hADAM8 will provide an insight whether hADAM8 involved in the 
neurodegenerative diseases caused by degeneration of MBP. Therefore testing 
hADAM8 against hMBP is very important. 
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6.4 Stability of soluble human and mouse ADAM8 
 
Schlomann et al., (2002) suggested storing pro-form mADAM8 at 4˚C for some time 
(up to 4 weeks) would leads to autocatalytic activity, generating the active protease. 
Although this contradicts with our findings in which purified soluble ADAM8 (mouse 
and human) are usually active. We investigated this phenomenon by incubating just 
purified sADAM8 for various periods. Probing active mouse and human ADAM8 did 
not show any autocatalytic activity, no other fragments than the original ones were 
significantly generated (Figures 3.3 and 3.9 respectively). Our explanation that it 
might be because their ADAM8 was not fully processed since it was produced in a 
bacterial system, or they used full length ADAM8 including the pro-domain. 
Therefore during the time of incubation pro-domain will be removed making the 
protease active. We used mammalian expression system and thus maturation and 
processing of ADAM8 will be according to the in vivo situation. Another possibility is 
that there might be co-purified protease that might cause degradation of their 
ADAM8. Anyway, this is the only study reported such phenomenon. Overall, we can 
argue that our expression system is valid and the products are very relevant to the in 
vivo situation.       
 
6.5 Cleavage of CD23 by human and mouse ADAM8 
 
CD23 or FcεRII, the low affinity IgE receptor, has been shown to play a role in the 
human immune response, in particular in the regulation of IgE synthesis (202). CD23 
is a type II transmembrane glycoprotein and found on a variety of cell types in 
humans including B cells, monocytes, eosinophils, dendritic and Langerhans cells (*). 
Two isoforms of CD23 exist in human, CD23a and CDb, which result from two 
different alternative splicing. CD23 is initially expressed as a membrane-bound 
protein, but it is shedded by an unknown metalloprotease (152,151) releasing the 
majority of the protein as a soluble protein (sCD23), which contains the stalk and 
lectin domains (130,162). The initial fragment that is released has a molecular mass of 
approximately 37kDa in human and 38kDa in mouse. Smaller fragments of sizes 
ranging from 33 to 12kDa in human and from 35 to 25kDa in mouse were also 
detected, all containing the lectin domain, are also seen. The stalk region of CD23 is 
located between the lectin domain and the transmembrane region. The murine CD23 
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stalk region contains four 21-aa repeats (122), whereas the human has three (119). It 
has also been noted that the stalk region contains a periodic heptad repeat containing a 
hydrophobic amino acid (usually leucine), which is characteristic for a leucine zipper 
motif, and it was suggested that CD23 might form a α helical coiled-coil. This coiled-
coil motif implies that CD23 exists as a multimer on the cell surface, which has been 
verified by cross-linking experiments (122). 
There is increasing evidence that soluble CD23 (sCD23) fragments either alone or in 
combination with cytokines regulate IgE synthesis, promote proliferation of B cells, 
and modulate monocytes activation (203,202,09). In addition, the presence of high 
amounts of serum sCD23 correlates well with allergic diseases in several reported 
studies (204,205). In this study we investigated the role of ADAM8 in shedding CD23 
and attempting to identify the cleavage sites.  
The long term goal is to inhibit processing of membrane-bound CD23 in order to 
control inappropriate IgE production which will provides excellent therapeutic 
opportunities.  
First we addressed the question of CD23 shedding by ADMA8 using various peptides 
derived from the CD23 stalk region. 
We synthesised three types of CD23 peptides, their sequences deduced from the stalk 
region containing putative cleavage sites. They contain the cleavage sites to generate 
either the 33 or 37kDa fragments. In separate experiments soluble mouse or human 
ADAM8 were incubated with these peptides and cleavage products were identified by 
MALDI-TOF mass spectrometry. The cleavage sites were identified and then 
compared with the amino termini of fragments generated by shedding from 
RPMI8888 B cells (152). Although peptides do not necessary form the in vivo 
conformation as membrane bound CD23 protein, such cleavage would argue in favour 
of ADAM8 as a metalloprotease candidate that is involved in the shedding process of 
CD23. Considering the cleavage sites identified by both human and mouse ADAM8, 
in both cases the cleavage sites were found to be identical in all peptides. This is 
could be because of the homology between them (more than 70%) or because the 
catalytic domains are very similar and therefore recognise the site.  
The next step was to find out whether ADAM8 can also cleave the CD23 ectodomain 
and what type of fragments are generated. CD23 ectodomain of various length were 
produced and incubated with either hADAM8 or mADAM8. One of them contains 
the entire extracellular domain (W45), and contains all potential cleavage sites, as 
Discussion 81
shown in figure 3.5. Soluble mADAM8-Fc generates 37, 27 and 25kDa fragments of 
CD23. In the presence of metalloprotease inhibitor (1,10 phenanothroline) no 
cleavage product was detected. In addition, another fragment (M150) that does not 
contains any known cleavage site, was not cleaved by mADAM8. This indicate that 
ADAM8 acts specifically in the predicted sites included in each fragment, referring to 
the peptide cleavage, mADAM8 did not generate 33kDa fragment, whereas 37kDa 
was generated and in addition smaller fragments detected (27 and 25kDa). It could be 
that the 37kDa is an intermediate product which might be further degraded into 
smaller fragments. This can be confirmed by carrying kinetic study in which various 
incubation times attempted and detect the products. In the same time fragments 
should be sequenced and identify the cleavage sites. This will provide very essential 
information about cleavage sites and whether 37kDa is an intermediate product or is it 
one of the main products.  
The results revealed from assays with mADAM8 were compared to another 
experiment was carried out using hADAM8. In this experiment the longest form of 
sCD23 containing all potential cleavage sites was used. The cleavage products were 
similar that generated by mADAM8 with the important exception that a 33kDa 
fragment was generated (figure 3.10C). This correlates with the derived peptide assay 
as hADAM8 cleaves the peptides similarly generating 37 and 33kDa. It seems that 
mouse and human ADAM8 behave differently at protein level. Cleavage products of 
hADAM8 are in correlation with what others found (96). The 33kDa fragment is 
believed to be very important in inflammation. It is the fragment believed to be 
responsible in eliciting allergic reactions.  
It has been reported previously that ADAM8 is the metalloprotease that is involved in 
the shedding of CD23 and one of the generated fragment was the 33kDa (96). 
Marolewski et al (1998)., demonstrated that CD23-processing belongs to the 
metalloprotease class and inhibition of the metalloprotease activity by 1,10-
phenanthroline and imidazole prevents the formation of the 37 and 33kDa in both 
membranes and solublised membranes. According to this study the enzyme 
responsible for CD23 release is membrane-anchored, as is CD23 itself.  
The interaction between CD23 and its processing enzyme could therefore be 
facilitated as well as controlled by the relative orientation of the two proteins in the 
membrane. This means that the metalloprotease involved in processing CD23 is 
expressed on the same cell surface and cis interaction takes place which leads to 
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processing CD23, alternatively, addition of soluble active ADMA8 to cells expressing 
CD23 or expression of each protein on different type of cells also possible and in this 
case processing CD23 occurs via trans-interaction. The evidence showed proteolytic 
ectodomain cleavage of CD23 by ADAM8 in cis was provided by Fourie et al., 
(2003). Co-transfection of active ADAM8 with CD23 led to CD23 processing and 
generation of 33kDa fragment. In trans-shedding CD23 was the most susceptible to 
ADAM8 ectodomain cleavage. Fourie et al., (2003) also demonstrated that the 
physical association between ADAM8 and CD23, this was one of the clearest 
evidence that hADAM8 is the metalloprotease responsible for processing of CD23. 
Marolewski et al., (1998) showed that CD23 processed from RPMI8866 B cell line is 
caused by an unknown metalloprotease. Fourie et al., (2003) explored the possibility 
that this protease activity was ADAM8. It was found that ADAM8-CD23 release in 
transfected cells was potently inhibited by MMP inhibitor II. The inhibitor showed 
similar inhibition of endogenous CD23 release in RPMI8866 cells.  
Figures 3.5 and 3.10 showed that both mouse and human ADAM8 generate 25kDa 
fragment, various studies have suggested that 25kDa fragment can be generated under 
some conditions either directly from the cell surface or rapidly from larger fragments 
by an unrelated mechanism involving an enzyme with characteristics of a cysteine 
protease (206,164). It seems that under the condition in which sCD23 was used, 
metalloprotease inhibition prevented any cleavage. Therefore, the cleavage was due to 
ADAM8. Such fragment is not detected from the cell surface might be because of the 
protein conformation, it been speculated that CD23 exist as trimer and the 
accessibility by the metalloprotease will be hindered. Solublization of CD23 might 
lead to conformational changes and therefore better accessibility to the cleavage site.    
Furthermore, it was verified that ADAM8 is expressed in RPMI8866 and JY cell 
lines. Lysates from both cell lines showed immunoreactive bands corresponds to 
molecular weights similar to the specific bands in ADAM8-tranfected cells (96).                                   
Although this study supported ADAM8 as a metalloprotease involved in generating 
biologically active fragments of CD23 but did not identify the cleavage site. 
Determining exact cleavage site and compare it with what already been published will 
shed the light where ADAM8 acts.  
On other hand, other metalloproteases might be involved and generation of such 
fragments are might be due to multi-metalloprotease action. This brings the argument 
about specific and selective metalloprotease inhibitors. Many of the compounds 
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available to date have been less selective. Of the four TIMPs (TIMP-1, -2, -3, and -4) 
only TIMP-1 showed slight inhibitory activity against ADAM8 (200). Also various 
hydroxamate-based metalloproteinase inhibitors were evaluated. CT435 so far is the 
most potential inhibitor, followed by CT572 and CT1399 whereas CT635 and 
CT2256 were poor inhibitors of ADAM8. Structure of CT572 and CT1399 have an 
extended side chain in P1', indicating that ADAM8 may resemble MMPs such as 
gelatinase A or collagenase-3 which have a deep S1' specificity pocket. At P2', the 
cyclohexylmethyl group of CT435, CT572 and CT1399 was preferred to the smaller 
isobutyl and tert-butyl groups of CT635 and CT2256, respectively. Considering the 
above data, it is believed that ADAM8 inhibitor potency can be obtained by 
optimisation of the P2' and P1' residues (200).  
 
6.6 Susceptibility of CD23 cleavage sites 
 
An attempt to find out whether mutating CD23 at predicted cleavage sites will render 
it more susceptible to mADAM8. Figure 3.6 showed that transfection of wild type 
CD23 and other mutants without mADAM8 into Cos-1 cells leads to generation 
various fragments. These fragments might be generated due the presence of other 
proteases expressed by Cos-1 cells. In the absence of mADAM8, only tiny amount of 
33kDa fragment generated from wild type and Q100A, whereas quite strong in K82E 
and more bands were detected as well. 
When mADAM8 and CD23 wild type were co-transfected, both 33 and 29kDa 
fragments were enhanced. Although the 33kDa fragment was weak, 29kDa was the 
main fragment in both mutants. In both wild type and K82E, 33kDa was generated in 
similar level. It seems that charge reversal mutation to glutamate decreased 
production of 37kDa but did not appear to significantly diminish formation of the 
33kDa fragment. Since the production of the 33kDa fragment was not diminished by 
the K82E mutation it can be inferred that sequential proteolysis is not obligatory, but 
instead the 37 and 33kDa fragments can be generated independently (207). 
 
6.7 Biding of soluble hADAM8-His6 to integrin subunits 
 
Integrins are cell adhesion molecules that consist of two noncovalently associated 
subunits, α and β. Although not related to each other, both subunits possess an α-
helical transmembrane domain spanning the plasma membrane once. The subfamily 
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of integrins sharing the β1 subunit is well known receptors for extracellular matrix 
molecules, such as collagens, laminins, and fibronectin. The subfamily of β3 subunit 
containing cytoadhesions comprises the platelet integrin, αIIbβ3 which binds 
fibrinogen/fibrin (208) and the vitronectin receptor αvβ3. The latter ones, along with 
several β1 integrin, such as the fibronectin receptor α5β1 integrin, recognise a linear 
arginyl-glycyl-aspartyl (RGD) sequence within their respective ligands, such as 
fibrinogen, fibronectin, and vitronectin (209). In contrast, the collagen binding 
integrins α1β1 and α2β1 recognize arginine and aspartate/glutamate residue in different 
collagen chains, which are in close proximity to each other within the triple helical 
collagenous framework of the collagen, thus forming a completely different spatial 
structure than the linear RGD peptide (110,111).  
In addition to their proteolytic function, several ADAMs have been shown to interact 
with the integrin family of cell surface receptors. The ADAM disintegrin-like 
domains are homologous to small non-enzymatic peptides isolated from the venom of 
snakes that function as antagonists of integrins (112). The direct interaction of sneak 
venom disintegrin peptides with integrins led to the hypothesis that the disintegrin-
like domains of ADAMs may function as integrin ligands. 
The disintegrin-like domains of ADAMs 1-3 expressed on the surface of sperm 
interact with the integrin α6β1 in association with CD9 and CD98 on the egg surface 
(73,52,213,214). Recognition of ADAMs 2 and 3 by α6β1 requires the residues DECD 
located within a region of the disintegrin domain, designated the disintegrin loop, that 
corresponds to an extended loop in the snake venom peptide that typically contains an 
RGD required for integrin binding (213,214, 215). 
Only human ADAM15 contains an RGD sequence within the disintegrin loop region 
and is recognised by the integrins αvβ3 and α5β1 (35,52,57). Although mouse 
ADAM15 lacks the RGD sequence found in the human homologue, both human and 
mouse ADAM15 as well as ADAM12 were shown to be recognized by the integrin 
α9β1 via residues outside the disintegrin loop (53). Other ADAM disintegrin-like 
domains reported to bind integrins are ADAM9, which is recognized by α6β1 and αvβ5 
(57,216), and ADAM23, which is recognized by αvβ3 (55).  
There is no information available about interaction between ADAM8 and integrin 
subunits. Here we used transfected CHO cells stably expressing various integrin 
subunits (α2, α3, α4, α6, αLβ2 and β3) (51,221,222,223,224,225). As it shown in figure 
3.12A, stably transfected CHO cells were highly expressing α3, α4, and α6, whereas α2 
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and β3 subunits were moderately expressed. Wild type did not show any signal or the 
level was below detection limit. The next step was to examine binding of soluble 
hADAM8-His6 with the cells expressing various integrin subunits. The outcome was 
very clear and consistent, that hADAM8-His6 showed bindings with transfected cells. 
A strong support that this interaction was due to hADAM8-His6 came from using wild 
type cells. There was no binding or any sort of signals indicating interaction between 
wild type cells and soluble hADAM8-His6.  
Although in most cases hADAM8-His6 showed binding with various integrin 
subunits, but there was some differences in term of the strength of the binding. The 
best binding was with αLβ2 and α6. Since α6 was highly expressed, the strength of 
binding might attributed to the expression level of these subunits. Whereas in case of 
αLβ2, this might be due to the combinatorial expression of the transfected subunits, in 
other word these subunits form a heterodimer in which hADAM8-His6 binds better as 
one entity or to each subunit individually. 
Because hADAM8-His6 interacted with all subunits been tested, the specificity is 
questionable. In our experiments we used the entire extracellular form of hADAM8, 
and it is unknown whether all or some bindings were due to other domains, also it is 
unknown if other domains contribute to this interaction.  
Using disintegrin domain alone or test each domain individually will provide clear 
answer about whether the binding is due to disintegrin domain or other domains. The 
only limitation of this is the stability of disintegrin domain on its own. Provided it is 
stable, this will provide more discrete evidence.  
It is believed that integrins expressed on cell surface are in active state, but many 
studies found out that cations (Mg2+ or Mn2+) are required for integrin activation. 
Therefore we investigated whether transfected integrin subunits require cations for 
their binding with soluble hADAM8-His6, we found that Mn2+ (2mM) was essential 
for their interaction with hADAM-His6. This is because Mn2+ is highly potent effector 
of several integrin-mediated adhesive events. It can ‘activate’ many integrins (217, 
218). Therefore we speculate that transfected integrin subunits were expressed as 
inactive. 
In addition to cation requirement, we attempted to find out whether interaction is 
temperature dependent. Thus we tested binding at various temperatures, 4˚C, room 
temperature (25˚C) and 37˚C. Binding at 4˚C was the always very reproducible and 
ideal, whereas at 37˚C, hADAM8-His found to be harmful. This could be because 
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integrin instability or might be because hADAM8-His6 at this temperature damage 
cells and consequently affect integrin subunits.  
We performed our binding experiments under suspension condition. Like others, 
binding of hADAM8-His6 to integrin subunits can be improved by utilizing solid-
phase cell adhesion assay. Adsorbing purified recombinant integrin subunits into 
solid-phase and then adding cells expressing hADAM8-His6, alternatively purified 
soluble ADAM8 adsorbed into solid-phase and cells expressing integrin subunits 
added. Bound cells can be quantified by assaying endogenous phosphatase activity 
(219). The reason behind this is that attaching to solid-phase could affects the 
conformation status of integrin subunits and therefore would leads to better 
interaction betweens metalloprotease and integrin subunits. 
 
6.8 Inhibition of soluble hADAM8-His6 to integrin subunits 
 
ADAMs are potential ligands for integrins due to the presence of identifiable integrin 
binding motifs within their disintegrin domain and by their homology to snake venom 
disintegrins, which can bind to integrins like αIIBβ3 and αVβ3. It has been found that 
many integrins recognise short linear amino acid sequences within their ligands. The 
best characterised motif is that containing the sequence Arg, Gly, Asp (RGD), which 
is present in several integrin ligands including fibronectin, vitronectin and von 
Willebrand factor. Human ADAM15 is the only ADAM identified to date containing 
an RGD motif within its disintegrin domain. Nath et al., (1999) showed that 
ADAM15 can bind to αVβ3 and α5β1 integrins. Binding also found to be RGD-
dependent. Also interaction between α5β1 and ADAM17 has been found to be RGD-
dependent (175).  
Both α4β1 and α4β7 were recognised by disintegrin domains of ADAM7 and 
ADAM28, whereas the disintegrin domain of ADAM33 exclusively recognised α9β1 
subunits (220).   
In order to find out if the interaction between the mentioned integrin subunits and 
hADAM8-His6 is depending on the sequences of the disintegrin loop. We synthesised 
cyclic peptide containing the disintegrin protruding loop which assumed as key factor 
in binding. Cells were preincubated with the peptide prior addition of hADMA8-His6. 
There was weak inhibition due to the presence of the peptide (figure 3.12C). In order 
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to find out whether such interaction is due direct interaction with disintegrin domain, 
it would be better to narrow down the interaction with disintegrin domain only.    
The ADAMs disintegrin domains generally lack RGD motifs. Integrin α9β1 
specifically interacts with the recombinant ADAMs12 and 15 disintegrin domains in 
RGD-independent manner (53). Although human ADAM8 does not contain RGD 
motif in its disintegrin domain but it binds to various integrin subunits. Therefore, in 
this case RGD is not an absolute prerequisite and we can not rule out the other 
domains (Cysteine-rich) might be involved in bindings of hADAM8-His to various 
integrin subunits i.e. soluble hADAM8-His6 to integrin subunits is not RGD 
dependent.  
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7. Conclusion 
 
The presented results show that soluble human and mouse ADAM8 are multifunction 
metalloproteases. Because of their high homology they recognise similar substrates. 
Both ADAMs cleaved peptides containing potential cleavage sites within identical 
sites of the CD23 stalk region. One of the striking outcomes was the generation of the 
33kDa fragment from the ectodomain of CD23 by human ADAM8. This fragment is 
very important in eliciting allergic reactions. Performance of cis and trans shedding 
should be the next investigation and developing specific metalloprotease protease 
inhibitors will be the ultimate goal as therapeutic intervention against allergic 
reactions. 
 
Few ADAMs so far have been shown to interact with integrins. In this study 
hADAM8 was shown to bind to various integrin subunits. Binding to integrins is most 
likely mediated by the disintegrin domain. Inhibition of binding by using cyclic 
peptides against the protruding loop of the disintegrin domain of human ADAM8 did 
not led to significant inhibition. Since the extracellular ADAM8 was used, binding 
could be due to the presence of other domains. In Intervention of cell cell interactions 
by inhibiting ADAM8 peptides that interfere integrin binding could be an important 
strategy to target ADAM8 function.      
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